CN113214240A - 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 - Google Patents
作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 Download PDFInfo
- Publication number
- CN113214240A CN113214240A CN202110695453.0A CN202110695453A CN113214240A CN 113214240 A CN113214240 A CN 113214240A CN 202110695453 A CN202110695453 A CN 202110695453A CN 113214240 A CN113214240 A CN 113214240A
- Authority
- CN
- China
- Prior art keywords
- ethyl
- dihydro
- pyrazole
- carboxamide
- methylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CHOZZQWROWREBD-UHFFFAOYSA-N N-(1,3-dihydropyrazol-2-yl)formamide Chemical class C(=O)NN1NC=CC1 CHOZZQWROWREBD-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 229940126202 P2X3 receptor antagonist Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 153
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 230000001404 mediated effect Effects 0.000 claims abstract description 6
- -1 heterocycloalkyl ketone Chemical class 0.000 claims description 86
- 238000002360 preparation method Methods 0.000 claims description 47
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 206010011224 Cough Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 208000002193 Pain Diseases 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 12
- YWXUUAFSFJYNHA-PBHICJAKSA-N ethyl N-methyl-N-[(4S)-5-(4-methylphenyl)-2-[[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]carbamoyl]-3,4-dihydropyrazol-4-yl]carbamate Chemical compound CCOC(=O)N(C)[C@H]1CN(N=C1C2=CC=C(C=C2)C)C(=O)N[C@H](C)C3=CN=C(N=C3)C(F)(F)F YWXUUAFSFJYNHA-PBHICJAKSA-N 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 235000015165 citric acid Nutrition 0.000 claims description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 235000011090 malic acid Nutrition 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 208000013116 chronic cough Diseases 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- NXJFILIWXOPBJK-CJNGLKHVSA-N (4S)-N-[(1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-5-(4-methylphenyl)-4-(2-oxopyrrolidin-1-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCCC3=O)C(=O)N[C@H](C)C4=NC(=NO4)C NXJFILIWXOPBJK-CJNGLKHVSA-N 0.000 claims description 4
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- HZWMEHUDNNEEBN-KSSFIOAISA-N (4S)-4-[acetyl(methyl)amino]-5-(4-methylphenyl)-N-[(1S)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N(C)C(=O)C)C(=O)N[C@@H](C)C3=CN=C(C=C3)C(F)(F)F HZWMEHUDNNEEBN-KSSFIOAISA-N 0.000 claims description 3
- WPNBCXQHYHBGRR-PBHICJAKSA-N (4S)-5-(4-methylphenyl)-4-(3-oxomorpholin-4-yl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOCC3=O)C(=O)N[C@H](C)C4=CN=C(N=C4)C(F)(F)F WPNBCXQHYHBGRR-PBHICJAKSA-N 0.000 claims description 3
- ADZKUIBSTPCZJS-QAPCUYQASA-N (4S)-5-(4-methylphenyl)-4-(3-oxomorpholin-4-yl)-N-[(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOCC3=O)C(=O)N[C@H](C)C4=CN=C(C=C4)C(F)(F)F ADZKUIBSTPCZJS-QAPCUYQASA-N 0.000 claims description 3
- UHQODAAXJRECEI-CJNGLKHVSA-N (4S)-N-[(1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-5-(4-methylphenyl)-4-(3-oxomorpholin-4-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOCC3=O)C(=O)N[C@H](C)C4=NC(=NO4)C UHQODAAXJRECEI-CJNGLKHVSA-N 0.000 claims description 3
- XEIFMVDYMWLSLZ-UTKZUKDTSA-N (4S)-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-(4-methyl-2-oxopiperazin-1-yl)-5-(4-methylphenyl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCN(CC3=O)C)C(=O)N[C@H](C)C4=CC=C(C=C4)Cl XEIFMVDYMWLSLZ-UTKZUKDTSA-N 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 125000006384 methylpyridyl group Chemical group 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- MIOPJNTWMNEORI-XVKPBYJWSA-N (R)-camphorsulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)C[C@H]1C2(C)C MIOPJNTWMNEORI-XVKPBYJWSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 claims description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 206010005063 Bladder pain Diseases 0.000 claims description 2
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 2
- 208000014181 Bronchial disease Diseases 0.000 claims description 2
- 206010006482 Bronchospasm Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 2
- 125000006396 chloropyrazinyl group Chemical group 0.000 claims description 2
- 125000006402 chloropyridazinyl group Chemical group 0.000 claims description 2
- 125000006390 chloropyrimidinyl group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000005805 dimethoxy phenyl group Chemical group 0.000 claims description 2
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical group O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 claims description 2
- 150000002576 ketones Chemical group 0.000 claims description 2
- 229940116298 l- malic acid Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 229940099690 malic acid Drugs 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000006399 methylpyrazinyl group Chemical group 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims description 2
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- PPVUWDCETZMPLT-UHFFFAOYSA-N 1,3-dihydropyrazole-2-carboxamide Chemical compound NC(=O)N1CC=CN1 PPVUWDCETZMPLT-UHFFFAOYSA-N 0.000 claims 16
- ZMZGJXZWHBZFEJ-BEFAXECRSA-N (4S)-4-(3-acetyl-2-oxoimidazolidin-1-yl)-5-(4-methylphenyl)-N-[(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCN(C3=O)C(=O)C)C(=O)N[C@H](C)C4=CN=C(C=C4)C(F)(F)F ZMZGJXZWHBZFEJ-BEFAXECRSA-N 0.000 claims 2
- JCFIBGQDKQVYBF-VGSWGCGISA-N (4S)-4-(3-acetyl-2-oxoimidazolidin-1-yl)-N-[(1R)-1-(4-cyanophenyl)ethyl]-5-(4-methylphenyl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCN(C3=O)C(=O)C)C(=O)N[C@H](C)C4=CC=C(C=C4)C#N JCFIBGQDKQVYBF-VGSWGCGISA-N 0.000 claims 2
- PWHLQEQUQHNUJB-UZLBHIALSA-N (4S)-4-(4-acetylpiperazin-1-yl)-5-(4-methylphenyl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCN(CC3)C(=O)C)C(=O)N[C@H](C)C4=CN=C(N=C4)C(F)(F)F PWHLQEQUQHNUJB-UZLBHIALSA-N 0.000 claims 2
- DBVZDEIEZRPZGR-UTKZUKDTSA-N (4S)-4-(4-acetylpiperazin-1-yl)-5-(4-methylphenyl)-N-[(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCN(CC3)C(=O)C)C(=O)N[C@H](C)C4=CN=C(C=C4)C(F)(F)F DBVZDEIEZRPZGR-UTKZUKDTSA-N 0.000 claims 2
- NOVPSYANPKYSHN-APWZRJJASA-N (4S)-4-(4-methyl-2-oxopiperazin-1-yl)-5-(4-methylphenyl)-N-[(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCN(CC3=O)C)C(=O)N[C@H](C)C4=CN=C(C=C4)C(F)(F)F NOVPSYANPKYSHN-APWZRJJASA-N 0.000 claims 2
- FKQXSGZSLAUAIA-APWZRJJASA-N (4S)-4-[[2-(dimethylamino)acetyl]-methylamino]-5-(4-methylphenyl)-N-[(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N(C)C(=O)CN(C)C)C(=O)N[C@H](C)C3=CN=C(C=C3)C(F)(F)F FKQXSGZSLAUAIA-APWZRJJASA-N 0.000 claims 2
- KBDHQGVXLWDVLS-DYVFJYSZSA-N (4S)-4-[acetyl(methyl)amino]-5-(4-methylphenyl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N(C)C(=O)C)C(=O)N[C@H](C)C3=CN=C(N=C3)C(F)(F)F KBDHQGVXLWDVLS-DYVFJYSZSA-N 0.000 claims 2
- PDPFNGOXZVFGGA-QRWLVFNGSA-N (4S)-4-[acetyl(methyl)amino]-5-(4-methylphenyl)-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N(C)C(=O)C)C(=O)N[C@H](C)C3=CC=C(C=C3)C(F)(F)F PDPFNGOXZVFGGA-QRWLVFNGSA-N 0.000 claims 2
- HZWMEHUDNNEEBN-KDOFPFPSSA-N (4S)-4-[acetyl(methyl)amino]-5-(4-methylphenyl)-N-[(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N(C)C(=O)C)C(=O)N[C@H](C)C3=CN=C(C=C3)C(F)(F)F HZWMEHUDNNEEBN-KDOFPFPSSA-N 0.000 claims 2
- DUMNSAMKTSMJRL-KDOFPFPSSA-N (4S)-4-[acetyl(methyl)amino]-N-[(1R)-1-(6-chloropyridin-3-yl)ethyl]-5-(4-methylphenyl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N(C)C(=O)C)C(=O)N[C@H](C)C3=CN=C(C=C3)Cl DUMNSAMKTSMJRL-KDOFPFPSSA-N 0.000 claims 2
- YSDHMVNMNQEOJQ-WBMJQRKESA-N (4S)-5-(4-chlorophenyl)-4-(3-oxomorpholin-4-yl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound C[C@H](C1=CN=C(N=C1)C(F)(F)F)NC(=O)N2C[C@@H](C(=N2)C3=CC=C(C=C3)Cl)N4CCOCC4=O YSDHMVNMNQEOJQ-WBMJQRKESA-N 0.000 claims 2
- FNYKKSJPFABUSB-PXAZEXFGSA-N (4S)-5-(4-chlorophenyl)-N-[(1R)-1-(2-methylpyrimidin-5-yl)ethyl]-4-(2-oxo-1,3-oxazolidin-3-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=NC=C(C=N1)[C@@H](C)NC(=O)N2C[C@@H](C(=N2)C3=CC=C(C=C3)Cl)N4CCOC4=O FNYKKSJPFABUSB-PXAZEXFGSA-N 0.000 claims 2
- UZWHRJQRYLQNDR-WBMJQRKESA-N (4S)-5-(4-chlorophenyl)-N-[(1R)-1-(6-methoxypyridazin-3-yl)ethyl]-4-(2-oxo-1,3-oxazolidin-3-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound C[C@H](C1=NN=C(C=C1)OC)NC(=O)N2C[C@@H](C(=N2)C3=CC=C(C=C3)Cl)N4CCOC4=O UZWHRJQRYLQNDR-WBMJQRKESA-N 0.000 claims 2
- BRFNDDOVQDYBFZ-WBMJQRKESA-N (4S)-5-(4-fluorophenyl)-4-(3-oxomorpholin-4-yl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound C[C@H](C1=CN=C(N=C1)C(F)(F)F)NC(=O)N2C[C@@H](C(=N2)C3=CC=C(C=C3)F)N4CCOCC4=O BRFNDDOVQDYBFZ-WBMJQRKESA-N 0.000 claims 2
- OTHTULXCPLQZLQ-KDOFPFPSSA-N (4S)-5-(4-fluorophenyl)-N-[(1R)-1-(5-methylpyrazin-2-yl)ethyl]-4-(2-oxopyrrolidin-1-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CN=C(C=N1)[C@@H](C)NC(=O)N2C[C@@H](C(=N2)C3=CC=C(C=C3)F)N4CCCC4=O OTHTULXCPLQZLQ-KDOFPFPSSA-N 0.000 claims 2
- ARMMBJVSDZYIIK-BEFAXECRSA-N (4S)-5-(4-fluorophenyl)-N-[(1R)-1-(6-methoxypyridin-3-yl)ethyl]-4-morpholin-4-yl-3,4-dihydropyrazole-2-carboxamide Chemical compound C[C@H](C1=CN=C(C=C1)OC)NC(=O)N2C[C@@H](C(=N2)C3=CC=C(C=C3)F)N4CCOCC4 ARMMBJVSDZYIIK-BEFAXECRSA-N 0.000 claims 2
- QLSRFMJQCBDJBV-DYVFJYSZSA-N (4S)-5-(4-methoxyphenyl)-4-(3-oxomorpholin-4-yl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound C[C@H](C1=CN=C(N=C1)C(F)(F)F)NC(=O)N2C[C@@H](C(=N2)C3=CC=C(C=C3)OC)N4CCOCC4=O QLSRFMJQCBDJBV-DYVFJYSZSA-N 0.000 claims 2
- LBDMIGHERGHEFJ-CJNGLKHVSA-N (4S)-5-(4-methylphenyl)-4-(2-oxo-1,3-oxazolidin-3-yl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOC3=O)C(=O)N[C@H](C)C4=CN=C(N=C4)C(F)(F)F LBDMIGHERGHEFJ-CJNGLKHVSA-N 0.000 claims 2
- VCXGXKNAWLOQMC-PBHICJAKSA-N (4S)-5-(4-methylphenyl)-4-(2-oxo-1,3-oxazolidin-3-yl)-N-[(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOC3=O)C(=O)N[C@H](C)C4=CN=C(C=C4)C(F)(F)F VCXGXKNAWLOQMC-PBHICJAKSA-N 0.000 claims 2
- IAHHPIAGMJULQE-PBHICJAKSA-N (4S)-5-(4-methylphenyl)-4-(2-oxopyrrolidin-1-yl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCCC3=O)C(=O)N[C@H](C)C4=CN=C(N=C4)C(F)(F)F IAHHPIAGMJULQE-PBHICJAKSA-N 0.000 claims 2
- COEIPGAPVLGWKL-BEFAXECRSA-N (4S)-5-(4-methylphenyl)-4-(2-oxopyrrolidin-1-yl)-N-[(1R)-1-[5-(trifluoromethyl)pyridin-2-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCCC3=O)C(=O)N[C@H](C)C4=NC=C(C=C4)C(F)(F)F COEIPGAPVLGWKL-BEFAXECRSA-N 0.000 claims 2
- APCHESNIWCPSAQ-QAPCUYQASA-N (4S)-5-(4-methylphenyl)-4-(2-oxopyrrolidin-1-yl)-N-[(1R)-1-[6-(trifluoromethoxy)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCCC3=O)C(=O)N[C@H](C)C4=CN=C(C=C4)OC(F)(F)F APCHESNIWCPSAQ-QAPCUYQASA-N 0.000 claims 2
- YGJLEBYQBUJGDI-QAPCUYQASA-N (4S)-5-(4-methylphenyl)-4-(2-oxopyrrolidin-1-yl)-N-[(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCCC3=O)C(=O)N[C@H](C)C4=CN=C(C=C4)C(F)(F)F YGJLEBYQBUJGDI-QAPCUYQASA-N 0.000 claims 2
- DZNNMZUCQZHALB-UZLBHIALSA-N (4S)-5-(4-methylphenyl)-4-(3-oxomorpholin-4-yl)-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOCC3=O)C(=O)N[C@H](C)C4=CC=C(C=C4)C(F)(F)F DZNNMZUCQZHALB-UZLBHIALSA-N 0.000 claims 2
- GYUAVNKQRMHCOO-PBHICJAKSA-N (4S)-5-(4-methylphenyl)-4-(3-oxomorpholin-4-yl)-N-[(1R)-1-[5-(trifluoromethyl)pyrazin-2-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOCC3=O)C(=O)N[C@H](C)C4=CN=C(C=N4)C(F)(F)F GYUAVNKQRMHCOO-PBHICJAKSA-N 0.000 claims 2
- UJMUZCWBTVQRMP-PBHICJAKSA-N (4S)-5-(4-methylphenyl)-4-(3-oxomorpholin-4-yl)-N-[(1R)-1-[6-(trifluoromethyl)pyridazin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOCC3=O)C(=O)N[C@H](C)C4=NN=C(C=C4)C(F)(F)F UJMUZCWBTVQRMP-PBHICJAKSA-N 0.000 claims 2
- KUSVMEQSZNMFBJ-APWZRJJASA-N (4S)-5-(4-methylphenyl)-4-(4-methylpiperazin-1-yl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCN(CC3)C)C(=O)N[C@H](C)C4=CN=C(N=C4)C(F)(F)F KUSVMEQSZNMFBJ-APWZRJJASA-N 0.000 claims 2
- NMIUGQLOWYYCER-QAPCUYQASA-N (4S)-5-(4-methylphenyl)-4-morpholin-4-yl-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOCC3)C(=O)N[C@H](C)C4=CN=C(N=C4)C(F)(F)F NMIUGQLOWYYCER-QAPCUYQASA-N 0.000 claims 2
- TWNZDILJKXGCQR-QAPCUYQASA-N (4S)-5-(4-methylphenyl)-N-[(1R)-1-(5-methylpyrazin-2-yl)ethyl]-4-(2-oxo-1,3-oxazolidin-3-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOC3=O)C(=O)N[C@H](C)C4=NC=C(N=C4)C TWNZDILJKXGCQR-QAPCUYQASA-N 0.000 claims 2
- GSVXRTLIWLTURY-CJNGLKHVSA-N (4S)-5-(5-methylpyridin-2-yl)-4-(2-oxo-1,3-oxazolidin-3-yl)-N-[(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CN=C(C=C1)C2=NN(C[C@@H]2N3CCOC3=O)C(=O)N[C@H](C)C4=CN=C(C=C4)C(F)(F)F GSVXRTLIWLTURY-CJNGLKHVSA-N 0.000 claims 2
- RMWPLJOGIOJFHO-APWZRJJASA-N (4S)-N-[(1R)-1-(1,3-benzodioxol-5-yl)ethyl]-5-(4-methylphenyl)-4-(2-oxopyrrolidin-1-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCCC3=O)C(=O)N[C@H](C)C4=CC5=C(C=C4)OCO5 RMWPLJOGIOJFHO-APWZRJJASA-N 0.000 claims 2
- KPOLEJTVAMRUQD-WBMJQRKESA-N (4S)-N-[(1R)-1-(2-chloropyrimidin-5-yl)ethyl]-5-(4-fluorophenyl)-4-(2-oxopyrrolidin-1-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound C[C@H](C1=CN=C(N=C1)Cl)NC(=O)N2C[C@@H](C(=N2)C3=CC=C(C=C3)F)N4CCCC4=O KPOLEJTVAMRUQD-WBMJQRKESA-N 0.000 claims 2
- OREAWMMKBGXMGF-APWZRJJASA-N (4S)-N-[(1R)-1-(3,4-dimethoxyphenyl)ethyl]-5-(4-methylphenyl)-4-(2-oxo-1,3-oxazolidin-3-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOC3=O)C(=O)N[C@H](C)C4=CC(=C(C=C4)OC)OC OREAWMMKBGXMGF-APWZRJJASA-N 0.000 claims 2
- PRFUSOCMMPDXCZ-DYVFJYSZSA-N (4S)-N-[(1R)-1-(5,6-difluoropyridin-3-yl)ethyl]-5-(4-methylphenyl)-4-(2-oxo-1,3-oxazolidin-3-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOC3=O)C(=O)N[C@H](C)C4=CC(=C(N=C4)F)F PRFUSOCMMPDXCZ-DYVFJYSZSA-N 0.000 claims 2
- QJOZKEQMUFGZTB-UZLBHIALSA-N (4S)-N-[(1R)-1-(5-methoxypyridin-2-yl)ethyl]-5-(4-methylphenyl)-4-(2-oxopyrrolidin-1-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCCC3=O)C(=O)N[C@H](C)C4=NC=C(C=C4)OC QJOZKEQMUFGZTB-UZLBHIALSA-N 0.000 claims 2
- PTHQUCQMSCDKGE-CJNGLKHVSA-N (4S)-N-[(1R)-1-(6-chloropyridazin-3-yl)ethyl]-5-(4-methylphenyl)-4-(2-oxo-1,3-oxazolidin-3-yl)-3,4-dihydropyrazole-2-carboxamide Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N3CCOC3=O)C(=O)N[C@H](C)C4=NN=C(C=C4)Cl PTHQUCQMSCDKGE-CJNGLKHVSA-N 0.000 claims 2
- YWXUUAFSFJYNHA-RHSMWYFYSA-N CCOC(N(C)[C@H](C1)C(C2=CC=C(C)C=C2)=NN1C(N[C@H](C)C1=CN=C(C(F)(F)F)N=C1)=O)=O Chemical compound CCOC(N(C)[C@H](C1)C(C2=CC=C(C)C=C2)=NN1C(N[C@H](C)C1=CN=C(C(F)(F)F)N=C1)=O)=O YWXUUAFSFJYNHA-RHSMWYFYSA-N 0.000 claims 2
- OREAWMMKBGXMGF-VQIMIIECSA-N C[C@H](C(C=C1)=CC(OC)=C1OC)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C(C=C1)=CC(OC)=C1OC)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=CC=C(C)C=C1)=O OREAWMMKBGXMGF-VQIMIIECSA-N 0.000 claims 2
- RMWPLJOGIOJFHO-VQIMIIECSA-N C[C@H](C(C=C1)=CC2=C1OCO2)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C(C=C1)=CC2=C1OCO2)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O RMWPLJOGIOJFHO-VQIMIIECSA-N 0.000 claims 2
- JCFIBGQDKQVYBF-VGOFRKELSA-N C[C@H](C(C=C1)=CC=C1C#N)NC(N(C[C@H]1N(CCN2C(C)=O)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C(C=C1)=CC=C1C#N)NC(N(C[C@H]1N(CCN2C(C)=O)C2=O)N=C1C1=CC=C(C)C=C1)=O JCFIBGQDKQVYBF-VGOFRKELSA-N 0.000 claims 2
- XEIFMVDYMWLSLZ-DYESRHJHSA-N C[C@H](C(C=C1)=CC=C1Cl)NC(N(C[C@H]1N(CCN(C)C2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C(C=C1)=CC=C1Cl)NC(N(C[C@H]1N(CCN(C)C2)C2=O)N=C1C1=CC=C(C)C=C1)=O XEIFMVDYMWLSLZ-DYESRHJHSA-N 0.000 claims 2
- QJOZKEQMUFGZTB-OXQOHEQNSA-N C[C@H](C(C=C1)=NC=C1OC)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C(C=C1)=NC=C1OC)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O QJOZKEQMUFGZTB-OXQOHEQNSA-N 0.000 claims 2
- PRFUSOCMMPDXCZ-CXAGYDPISA-N C[C@H](C(C=N1)=CC(F)=C1F)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C(C=N1)=CC(F)=C1F)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=CC=C(C)C=C1)=O PRFUSOCMMPDXCZ-CXAGYDPISA-N 0.000 claims 2
- APCHESNIWCPSAQ-CRAIPNDOSA-N C[C@H](C(C=N1)=CC=C1OC(F)(F)F)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C(C=N1)=CC=C1OC(F)(F)F)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O APCHESNIWCPSAQ-CRAIPNDOSA-N 0.000 claims 2
- ARMMBJVSDZYIIK-DNVCBOLYSA-N C[C@H](C(C=N1)=CC=C1OC)NC(N(C[C@H]1N2CCOCC2)N=C1C(C=C1)=CC=C1F)=O Chemical compound C[C@H](C(C=N1)=CC=C1OC)NC(N(C[C@H]1N2CCOCC2)N=C1C(C=C1)=CC=C1F)=O ARMMBJVSDZYIIK-DNVCBOLYSA-N 0.000 claims 2
- PTHQUCQMSCDKGE-CZUORRHYSA-N C[C@H](C(N=N1)=CC=C1Cl)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C(N=N1)=CC=C1Cl)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=CC=C(C)C=C1)=O PTHQUCQMSCDKGE-CZUORRHYSA-N 0.000 claims 2
- UZWHRJQRYLQNDR-MLGOLLRUSA-N C[C@H](C(N=N1)=CC=C1OC)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C(C=C1)=CC=C1Cl)=O Chemical compound C[C@H](C(N=N1)=CC=C1OC)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C(C=C1)=CC=C1Cl)=O UZWHRJQRYLQNDR-MLGOLLRUSA-N 0.000 claims 2
- PDPFNGOXZVFGGA-FOIQADDNSA-N C[C@H](C1=CC=C(C(F)(F)F)C=C1)NC(N(C[C@H]1N(C)C(C)=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)C=C1)NC(N(C[C@H]1N(C)C(C)=O)N=C1C1=CC=C(C)C=C1)=O PDPFNGOXZVFGGA-FOIQADDNSA-N 0.000 claims 2
- DZNNMZUCQZHALB-OXQOHEQNSA-N C[C@H](C1=CC=C(C(F)(F)F)C=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)C=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O DZNNMZUCQZHALB-OXQOHEQNSA-N 0.000 claims 2
- HZWMEHUDNNEEBN-RDTXWAMCSA-N C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(C)C(C)=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(C)C(C)=O)N=C1C1=CC=C(C)C=C1)=O HZWMEHUDNNEEBN-RDTXWAMCSA-N 0.000 claims 2
- FKQXSGZSLAUAIA-VQIMIIECSA-N C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(C)C(CN(C)C)=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(C)C(CN(C)C)=O)N=C1C1=CC=C(C)C=C1)=O FKQXSGZSLAUAIA-VQIMIIECSA-N 0.000 claims 2
- PWOMOZYMRJDQDM-CXAGYDPISA-N C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(C)C(OC)=O)N=C1C(C=C1)=CC=C1OC)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(C)C(OC)=O)N=C1C(C=C1)=CC=C1OC)=O PWOMOZYMRJDQDM-CXAGYDPISA-N 0.000 claims 2
- DBVZDEIEZRPZGR-DYESRHJHSA-N C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CC2)CCN2C(C)=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CC2)CCN2C(C)=O)N=C1C1=CC=C(C)C=C1)=O DBVZDEIEZRPZGR-DYESRHJHSA-N 0.000 claims 2
- YGJLEBYQBUJGDI-CRAIPNDOSA-N C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O YGJLEBYQBUJGDI-CRAIPNDOSA-N 0.000 claims 2
- NOVPSYANPKYSHN-VQIMIIECSA-N C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCN(C)C2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCN(C)C2)C2=O)N=C1C1=CC=C(C)C=C1)=O NOVPSYANPKYSHN-VQIMIIECSA-N 0.000 claims 2
- ZMZGJXZWHBZFEJ-DNVCBOLYSA-N C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCN2C(C)=O)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCN2C(C)=O)C2=O)N=C1C1=CC=C(C)C=C1)=O ZMZGJXZWHBZFEJ-DNVCBOLYSA-N 0.000 claims 2
- GSVXRTLIWLTURY-CZUORRHYSA-N C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=NC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=NC=C(C)C=C1)=O GSVXRTLIWLTURY-CZUORRHYSA-N 0.000 claims 2
- ADZKUIBSTPCZJS-CRAIPNDOSA-N C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O ADZKUIBSTPCZJS-CRAIPNDOSA-N 0.000 claims 2
- UJMUZCWBTVQRMP-RHSMWYFYSA-N C[C@H](C1=CC=C(C(F)(F)F)N=N1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CC=C(C(F)(F)F)N=N1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O UJMUZCWBTVQRMP-RHSMWYFYSA-N 0.000 claims 2
- KBDHQGVXLWDVLS-CXAGYDPISA-N C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(C)C(C)=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(C)C(C)=O)N=C1C1=CC=C(C)C=C1)=O KBDHQGVXLWDVLS-CXAGYDPISA-N 0.000 claims 2
- PWHLQEQUQHNUJB-OXQOHEQNSA-N C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CC2)CCN2C(C)=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CC2)CCN2C(C)=O)N=C1C1=CC=C(C)C=C1)=O PWHLQEQUQHNUJB-OXQOHEQNSA-N 0.000 claims 2
- IAHHPIAGMJULQE-RHSMWYFYSA-N C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O IAHHPIAGMJULQE-RHSMWYFYSA-N 0.000 claims 2
- LBDMIGHERGHEFJ-CZUORRHYSA-N C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=CC=C(C)C=C1)=O LBDMIGHERGHEFJ-CZUORRHYSA-N 0.000 claims 2
- YSDHMVNMNQEOJQ-MLGOLLRUSA-N C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C(C=C1)=CC=C1Cl)=O Chemical compound C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C(C=C1)=CC=C1Cl)=O YSDHMVNMNQEOJQ-MLGOLLRUSA-N 0.000 claims 2
- QLSRFMJQCBDJBV-CXAGYDPISA-N C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C(C=C1)=CC=C1OC)=O Chemical compound C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C(C=C1)=CC=C1OC)=O QLSRFMJQCBDJBV-CXAGYDPISA-N 0.000 claims 2
- WPNBCXQHYHBGRR-RHSMWYFYSA-N C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O WPNBCXQHYHBGRR-RHSMWYFYSA-N 0.000 claims 2
- KUSVMEQSZNMFBJ-VQIMIIECSA-N C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N2CCN(C)CC2)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N2CCN(C)CC2)N=C1C1=CC=C(C)C=C1)=O KUSVMEQSZNMFBJ-VQIMIIECSA-N 0.000 claims 2
- NMIUGQLOWYYCER-CRAIPNDOSA-N C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N2CCOCC2)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N2CCOCC2)N=C1C1=CC=C(C)C=C1)=O NMIUGQLOWYYCER-CRAIPNDOSA-N 0.000 claims 2
- FNYKKSJPFABUSB-SJKOYZFVSA-N C[C@H](C1=CN=C(C)N=C1)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C(C=C1)=CC=C1Cl)=O Chemical compound C[C@H](C1=CN=C(C)N=C1)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C(C=C1)=CC=C1Cl)=O FNYKKSJPFABUSB-SJKOYZFVSA-N 0.000 claims 2
- NXJFILIWXOPBJK-CZUORRHYSA-N C[C@H](C1=NC(C)=NO1)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=NC(C)=NO1)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O NXJFILIWXOPBJK-CZUORRHYSA-N 0.000 claims 2
- UHQODAAXJRECEI-CZUORRHYSA-N C[C@H](C1=NC(C)=NO1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=NC(C)=NO1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O UHQODAAXJRECEI-CZUORRHYSA-N 0.000 claims 2
- COEIPGAPVLGWKL-DNVCBOLYSA-N C[C@H](C1=NC=C(C(F)(F)F)C=C1)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=NC=C(C(F)(F)F)C=C1)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C1=CC=C(C)C=C1)=O COEIPGAPVLGWKL-DNVCBOLYSA-N 0.000 claims 2
- GYUAVNKQRMHCOO-RHSMWYFYSA-N C[C@H](C1=NC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=NC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(CCOC2)C2=O)N=C1C1=CC=C(C)C=C1)=O GYUAVNKQRMHCOO-RHSMWYFYSA-N 0.000 claims 2
- OTHTULXCPLQZLQ-RDTXWAMCSA-N C[C@H](C1=NC=C(C)N=C1)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C(C=C1)=CC=C1F)=O Chemical compound C[C@H](C1=NC=C(C)N=C1)NC(N(C[C@H]1N(CCC2)C2=O)N=C1C(C=C1)=CC=C1F)=O OTHTULXCPLQZLQ-RDTXWAMCSA-N 0.000 claims 2
- TWNZDILJKXGCQR-CRAIPNDOSA-N C[C@H](C1=NC=C(C)N=C1)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@H](C1=NC=C(C)N=C1)NC(N(C[C@H]1N(CCO2)C2=O)N=C1C1=CC=C(C)C=C1)=O TWNZDILJKXGCQR-CRAIPNDOSA-N 0.000 claims 2
- PWOMOZYMRJDQDM-DYVFJYSZSA-N methyl N-[(4S)-5-(4-methoxyphenyl)-2-[[(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]carbamoyl]-3,4-dihydropyrazol-4-yl]-N-methylcarbamate Chemical compound C[C@H](C1=CN=C(C=C1)C(F)(F)F)NC(=O)N2C[C@@H](C(=N2)C3=CC=C(C=C3)OC)N(C)C(=O)OC PWOMOZYMRJDQDM-DYVFJYSZSA-N 0.000 claims 2
- HZWMEHUDNNEEBN-KBXCAEBGSA-N C[C@@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(C)C(C)=O)N=C1C1=CC=C(C)C=C1)=O Chemical compound C[C@@H](C1=CC=C(C(F)(F)F)N=C1)NC(N(C[C@H]1N(C)C(C)=O)N=C1C1=CC=C(C)C=C1)=O HZWMEHUDNNEEBN-KBXCAEBGSA-N 0.000 claims 1
- 230000000274 adsorptive effect Effects 0.000 claims 1
- 125000006378 chloropyridyl group Chemical group 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 125000006393 methylpyrimidinyl group Chemical group 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 125000006387 trifluoromethyl pyridyl group Chemical group 0.000 claims 1
- 102100040460 P2X purinoceptor 3 Human genes 0.000 abstract description 29
- 101710189970 P2X purinoceptor 3 Proteins 0.000 abstract description 29
- 102000005962 receptors Human genes 0.000 abstract description 6
- 108020003175 receptors Proteins 0.000 abstract description 6
- 108091005462 Cation channels Proteins 0.000 abstract description 4
- 239000005557 antagonist Substances 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 111
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 45
- 238000003756 stirring Methods 0.000 description 45
- 238000003786 synthesis reaction Methods 0.000 description 45
- 230000002829 reductive effect Effects 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 42
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- 239000000243 solution Substances 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 33
- 238000001914 filtration Methods 0.000 description 32
- 239000012074 organic phase Substances 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 28
- 238000001035 drying Methods 0.000 description 28
- 239000000706 filtrate Substances 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- 239000000543 intermediate Substances 0.000 description 26
- 239000007832 Na2SO4 Substances 0.000 description 24
- 229910052938 sodium sulfate Inorganic materials 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 239000012071 phase Substances 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 238000010898 silica gel chromatography Methods 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 16
- 238000002156 mixing Methods 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 239000007858 starting material Substances 0.000 description 14
- 239000011550 stock solution Substances 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000012224 working solution Substances 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 11
- 229940126208 compound 22 Drugs 0.000 description 11
- 229960003088 loratadine Drugs 0.000 description 11
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 241000700198 Cavia Species 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229940125904 compound 1 Drugs 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 9
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 238000010791 quenching Methods 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- HLWURFKMDLAKOD-UHFFFAOYSA-N 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide Chemical compound C1=C(S(N)(=O)=O)C(OC)=CC(C(C)C)=C1OC1=CN=C(N)N=C1N HLWURFKMDLAKOD-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000035622 drinking Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- VZKFDBDBHDMKHK-GSVOUGTGSA-N (1r)-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethanamine Chemical compound C[C@@H](N)C1=NC(C)=NO1 VZKFDBDBHDMKHK-GSVOUGTGSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- NMFKACMVCRUBJJ-SCSAIBSYSA-N (1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethanamine Chemical compound C[C@@H](N)C1=CN=C(C(F)(F)F)N=C1 NMFKACMVCRUBJJ-SCSAIBSYSA-N 0.000 description 5
- GUMZDWPMXGQNBG-ZCFIWIBFSA-N (1r)-1-[4-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@@H](N)C1=CC=C(C(F)(F)F)C=C1 GUMZDWPMXGQNBG-ZCFIWIBFSA-N 0.000 description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- GVAMFOVLZBUOJP-UHFFFAOYSA-N CC(C)(C)OC(N(C)C(C1)C(C2=CC=C(C)C=C2)=NN1C(Cl)=O)=O Chemical compound CC(C)(C)OC(N(C)C(C1)C(C2=CC=C(C)C=C2)=NN1C(Cl)=O)=O GVAMFOVLZBUOJP-UHFFFAOYSA-N 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 5
- 102000002294 Purinergic P2X Receptors Human genes 0.000 description 5
- 108010000836 Purinergic P2X Receptors Proteins 0.000 description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000007831 electrophysiology Effects 0.000 description 5
- 238000002001 electrophysiology Methods 0.000 description 5
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008098 formaldehyde solution Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 4
- 238000002552 multiple reaction monitoring Methods 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- RFVSBDFGCLEJAT-QAPCUYQASA-N tert-butyl N-methyl-N-[(4S)-5-(4-methylphenyl)-2-[[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]carbamoyl]-3,4-dihydropyrazol-4-yl]carbamate Chemical compound CC1=CC=C(C=C1)C2=NN(C[C@@H]2N(C)C(=O)OC(C)(C)C)C(=O)N[C@H](C)C3=CN=C(N=C3)C(F)(F)F RFVSBDFGCLEJAT-QAPCUYQASA-N 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- WLWNRAWQDZRXMB-YLFCFFPRSA-N (2r,3r,4r,5s)-n,3,4,5-tetrahydroxy-1-(4-phenoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 WLWNRAWQDZRXMB-YLFCFFPRSA-N 0.000 description 3
- GAUDQBASERVUGM-UHFFFAOYSA-N 2-(trifluoromethyl)pyrimidine-5-carbaldehyde Chemical compound FC(F)(F)C1=NC=C(C=O)C=N1 GAUDQBASERVUGM-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GKEULTRCRNEYQX-UHFFFAOYSA-N CC(C=C1)=CC=C1C(C(C1)N(CCOC2)C2=O)=NN1C(Cl)=O Chemical compound CC(C=C1)=CC=C1C(C(C1)N(CCOC2)C2=O)=NN1C(Cl)=O GKEULTRCRNEYQX-UHFFFAOYSA-N 0.000 description 3
- 235000001258 Cinchona calisaya Nutrition 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102100040479 P2X purinoceptor 2 Human genes 0.000 description 3
- 101710189968 P2X purinoceptor 2 Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 229960000948 quinine Drugs 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- MVECYTHTNWUPEJ-UHFFFAOYSA-N 1-[2-(4-methylphenyl)-2-oxoethyl]pyrrolidin-2-one Chemical compound C1=CC(C)=CC=C1C(=O)CN1C(=O)CCC1 MVECYTHTNWUPEJ-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 2
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 2
- QRJMZYLYPCAHFU-UHFFFAOYSA-N 4-[2-(4-methylphenyl)-2-oxoethyl]morpholin-3-one Chemical compound C1=CC(C)=CC=C1C(=O)CN1C(=O)COCC1 QRJMZYLYPCAHFU-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KOGFICKCWVJNNJ-UHFFFAOYSA-N CC(C=C1)=CC=C1C(C(C1)N(CCC2)C2=O)=NN1C(Cl)=O Chemical compound CC(C=C1)=CC=C1C(C(C1)N(CCC2)C2=O)=NN1C(Cl)=O KOGFICKCWVJNNJ-UHFFFAOYSA-N 0.000 description 2
- BSIZRIZLXWXAAY-UHFFFAOYSA-N CC(C=C1)=CC=C1C(C(C1)N2N=CC=C2)=NN1C(Cl)=O Chemical compound CC(C=C1)=CC=C1C(C(C1)N2N=CC=C2)=NN1C(Cl)=O BSIZRIZLXWXAAY-UHFFFAOYSA-N 0.000 description 2
- JLWABPNLPANOIM-UHFFFAOYSA-N CC(N(C)C(C1)C(C2=CC=C(C)C=C2)=NN1C(Cl)=O)=O Chemical compound CC(N(C)C(C1)C(C2=CC=C(C)C=C2)=NN1C(Cl)=O)=O JLWABPNLPANOIM-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 101000614335 Homo sapiens P2X purinoceptor 2 Proteins 0.000 description 2
- 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 description 2
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 206010036018 Pollakiuria Diseases 0.000 description 2
- 102100030302 TBC1 domain family member 8 Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000003934 aromatic aldehydes Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- QVHJQCGUWFKTSE-RXMQYKEDSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-RXMQYKEDSA-N 0.000 description 1
- ANAMCEKSRDPIPX-GFGQVAFXSA-N (2s)-n-[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanamide Chemical compound NC(N)=NCCC[C@@H](C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)CC1=CC=CC=C1 ANAMCEKSRDPIPX-GFGQVAFXSA-N 0.000 description 1
- 239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 description 1
- YFDYEHIAUKXEDK-UHFFFAOYSA-N (n-hydroxy-c-methylcarbonimidoyl)azanium;chloride Chemical compound Cl.C\C(N)=N\O YFDYEHIAUKXEDK-UHFFFAOYSA-N 0.000 description 1
- NNKXWRRDHYTHFP-HZQSTTLBSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydron;dichloride Chemical compound Cl.Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 NNKXWRRDHYTHFP-HZQSTTLBSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- JOZKWAOWKKCEGG-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-morpholin-4-ylethanone Chemical compound C1=CC(F)=CC=C1C(=O)CN1CCOCC1 JOZKWAOWKKCEGG-UHFFFAOYSA-N 0.000 description 1
- VEBBGMUZELBUGC-UHFFFAOYSA-N 1-(4-methylphenyl)-2-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1CC(=O)C1=CC=C(C)C=C1 VEBBGMUZELBUGC-UHFFFAOYSA-N 0.000 description 1
- YCKYFDHMRZUKDD-UHFFFAOYSA-N 1-(4-methylphenyl)-2-morpholin-4-ylethanone Chemical compound C1=CC(C)=CC=C1C(=O)CN1CCOCC1 YCKYFDHMRZUKDD-UHFFFAOYSA-N 0.000 description 1
- OPBQJPOXKKQXMA-UHFFFAOYSA-N 1-[2-(4-fluorophenyl)-2-oxoethyl]pyrrolidin-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CN1C(=O)CCC1 OPBQJPOXKKQXMA-UHFFFAOYSA-N 0.000 description 1
- DQUXRDXABWIYEL-UHFFFAOYSA-N 1-[2-(5-methylpyridin-2-yl)-2-oxoethyl]pyrrolidin-2-one Chemical compound CC1=CN=C(C=C1)C(=O)CN2CCCC2=O DQUXRDXABWIYEL-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- MBWYBYVWGHUBHI-UHFFFAOYSA-N 1-acetyl-3-[2-(4-methylphenyl)-2-oxoethyl]imidazolidin-2-one Chemical compound CC1=CC=C(C=C1)C(=O)CN2CCN(C2=O)C(=O)C MBWYBYVWGHUBHI-UHFFFAOYSA-N 0.000 description 1
- RDUFFOJJIAWPON-UHFFFAOYSA-N 1-methyl-3-[2-(4-methylphenyl)-2-oxoethyl]imidazolidin-2-one Chemical compound O=C1N(C)CCN1CC(=O)C1=CC=C(C)C=C1 RDUFFOJJIAWPON-UHFFFAOYSA-N 0.000 description 1
- JRBNCQRYNGWBKU-UHFFFAOYSA-N 2-(4-acetylpiperazin-1-yl)-1-(4-methylphenyl)ethanone Chemical compound C1CN(C(=O)C)CCN1CC(=O)C1=CC=C(C)C=C1 JRBNCQRYNGWBKU-UHFFFAOYSA-N 0.000 description 1
- LJYQVOPFBNMTKJ-UHFFFAOYSA-N 2-chloropyrimidine-5-carbaldehyde Chemical compound ClC1=NC=C(C=O)C=N1 LJYQVOPFBNMTKJ-UHFFFAOYSA-N 0.000 description 1
- IJBONYUNKRDIFC-UHFFFAOYSA-N 2-methylpyrimidine-5-carbaldehyde Chemical compound CC1=NC=C(C=O)C=N1 IJBONYUNKRDIFC-UHFFFAOYSA-N 0.000 description 1
- UEDGBEZROGCNCY-UHFFFAOYSA-N 3-[2-(4-chlorophenyl)-2-oxoethyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)CN1C(=O)OCC1 UEDGBEZROGCNCY-UHFFFAOYSA-N 0.000 description 1
- REXNNBXJVACUML-UHFFFAOYSA-N 3-[2-(4-methylphenyl)-2-oxoethyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(C)=CC=C1C(=O)CN1C(=O)OCC1 REXNNBXJVACUML-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MQNAMFXRHRKWKJ-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)-2-oxoethyl]morpholin-3-one Chemical compound C1=CC(Cl)=CC=C1C(=O)CN1C(=O)COCC1 MQNAMFXRHRKWKJ-UHFFFAOYSA-N 0.000 description 1
- XBLXUWQNFNRZEQ-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-2-oxoethyl]morpholin-3-one Chemical class C1=CC(F)=CC=C1C(=O)CN1C(=O)COCC1 XBLXUWQNFNRZEQ-UHFFFAOYSA-N 0.000 description 1
- ICZJCHAUECYWJG-UHFFFAOYSA-N 4-[2-(4-methoxyphenyl)-2-oxoethyl]morpholin-3-one Chemical compound C1=CC(OC)=CC=C1C(=O)CN1C(=O)COCC1 ICZJCHAUECYWJG-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 1
- VXFNJRUETUIAJW-UHFFFAOYSA-N 4-methyl-1-[2-(4-methylphenyl)-2-oxoethyl]piperazin-2-one Chemical compound CC1=CC=C(C=C1)C(=O)CN2CCN(CC2=O)C VXFNJRUETUIAJW-UHFFFAOYSA-N 0.000 description 1
- JFKTYXKBSWABMV-UHFFFAOYSA-N 5,6-difluoropyridine-3-carbaldehyde Chemical compound FC1=CC(C=O)=CN=C1F JFKTYXKBSWABMV-UHFFFAOYSA-N 0.000 description 1
- SGTOICWGZDQSSE-UHFFFAOYSA-N 5-(trifluoromethyl)piperazine-2-carbaldehyde Chemical compound C1C(NCC(N1)C(F)(F)F)C=O SGTOICWGZDQSSE-UHFFFAOYSA-N 0.000 description 1
- JJDDVGAESNBKMY-UHFFFAOYSA-N 5-(trifluoromethyl)pyridine-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)N=C1 JJDDVGAESNBKMY-UHFFFAOYSA-N 0.000 description 1
- CTYUCLSCBVSTAA-UHFFFAOYSA-N 5-methoxypyridine-2-carbaldehyde Chemical compound COC1=CC=C(C=O)N=C1 CTYUCLSCBVSTAA-UHFFFAOYSA-N 0.000 description 1
- NRHYVDHQQYZPHM-UHFFFAOYSA-N 5-methylpiperazine-2-carbaldehyde Chemical compound CC1CNC(CN1)C=O NRHYVDHQQYZPHM-UHFFFAOYSA-N 0.000 description 1
- IJSXYDLSHMGUGT-UHFFFAOYSA-N 6-(trifluoromethoxy)pyridine-3-carbaldehyde Chemical compound FC(F)(F)OC1=CC=C(C=O)C=N1 IJSXYDLSHMGUGT-UHFFFAOYSA-N 0.000 description 1
- DJEWMKQZOIZESF-UHFFFAOYSA-N 6-(trifluoromethyl)pyridazine-3-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)N=N1 DJEWMKQZOIZESF-UHFFFAOYSA-N 0.000 description 1
- MRPAGRCGPAXOGS-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=N1 MRPAGRCGPAXOGS-UHFFFAOYSA-N 0.000 description 1
- YDHRPQYMQCOQQT-UHFFFAOYSA-N 6-chloropyridazine-3-carbaldehyde Chemical compound ClC1=CC=C(C=O)N=N1 YDHRPQYMQCOQQT-UHFFFAOYSA-N 0.000 description 1
- AFWWKZCPPRPDQK-UHFFFAOYSA-N 6-chloropyridine-3-carbaldehyde Chemical compound ClC1=CC=C(C=O)C=N1 AFWWKZCPPRPDQK-UHFFFAOYSA-N 0.000 description 1
- DMZWOPABKPRESI-UHFFFAOYSA-N 6-methoxypyridazine-3-carbaldehyde Chemical compound COC1=CC=C(C=O)N=N1 DMZWOPABKPRESI-UHFFFAOYSA-N 0.000 description 1
- CTAIEPPAOULMFY-UHFFFAOYSA-N 6-methoxypyridine-3-carbaldehyde Chemical compound COC1=CC=C(C=O)C=N1 CTAIEPPAOULMFY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- LSPZRPMZORXXAT-UHFFFAOYSA-N CC(C=C1)=CC=C1C1=NNCC1N(CCN(C)C1)C1=O Chemical compound CC(C=C1)=CC=C1C1=NNCC1N(CCN(C)C1)C1=O LSPZRPMZORXXAT-UHFFFAOYSA-N 0.000 description 1
- ZYNGGOTZCMOCHR-UHFFFAOYSA-N CC(C=C1)=CC=C1C1=NNCC1N1N=CC=C1 Chemical compound CC(C=C1)=CC=C1C1=NNCC1N1N=CC=C1 ZYNGGOTZCMOCHR-UHFFFAOYSA-N 0.000 description 1
- ALKFGMJBTSRJCV-UHFFFAOYSA-N CN(CC(=O)c1ccc(C)cc1)C(=O)OC(C)(C)C Chemical compound CN(CC(=O)c1ccc(C)cc1)C(=O)OC(C)(C)C ALKFGMJBTSRJCV-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 101000614332 Homo sapiens P2X purinoceptor 3 Proteins 0.000 description 1
- 101001098179 Homo sapiens P2X purinoceptor 4 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- AVXQPEKZIGPIJW-UHFFFAOYSA-N N3-cyclopropyl-7-[(4-propan-2-ylphenyl)methyl]pyrrolo[3,2-f]quinazoline-1,3-diamine Chemical compound C1=CC(C(C)C)=CC=C1CN1C(C=CC=2C3=C(N)N=C(NC4CC4)N=2)=C3C=C1 AVXQPEKZIGPIJW-UHFFFAOYSA-N 0.000 description 1
- 102100040444 P2X purinoceptor 1 Human genes 0.000 description 1
- 101710189973 P2X purinoceptor 1 Proteins 0.000 description 1
- 102100037601 P2X purinoceptor 4 Human genes 0.000 description 1
- 101710189967 P2X purinoceptor 4 Proteins 0.000 description 1
- 108010044027 PAR-1-activating peptide Proteins 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 108050009310 Protease-activated receptors Proteins 0.000 description 1
- 102000002020 Protease-activated receptors Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000608924 Whitea Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- BKYHTWFRZPRHNM-UHFFFAOYSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-[3-(acetyloxymethoxy)-6-oxoxanthen-9-yl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC(C2=C3C=CC(=O)C=C3OC3=CC(OCOC(C)=O)=CC=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O BKYHTWFRZPRHNM-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 108091008698 baroreceptors Proteins 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 230000008050 pain signaling Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical class O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 210000001774 pressoreceptor Anatomy 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000013062 quality control Sample Substances 0.000 description 1
- 229960001811 quinine hydrochloride Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- KRZNFMNCDPFVSA-ZCFIWIBFSA-N tert-butyl n-[(1r)-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C)C1=NC(C)=NO1 KRZNFMNCDPFVSA-ZCFIWIBFSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种N‑甲酰胺基吡唑啉类衍生物,具有通式(I)的化合物或其对映异构体、非对映异构体、差向异构体、外消旋体,或其在药学上可接受的盐。所述化合物是配体门控非选择性阳离子通道受体亚型P2X3的拮抗剂,可用治疗或预防由P2X3受体介导的各类疾病。
Description
技术领域
本发明属于医药领域,涉及一种作为配体门控非选择性阳离子通道受体亚型P2X3抑制剂的N-甲酰胺基吡唑啉类衍生物,及其在制备治疗由P2X3介导的疾病药物中的应用。
背景技术
P2X3是一种配体门控非选择性阳离子通道受体亚型,归属于嘌呤能受体P2大类中的离子型P2X受体,最初于1995年在哺乳动物中克隆(Chen C等,Nature,1995,428;Lewis,C等,Nature,1995,432),至今,在哺乳动物中已克隆的P2X受体亚型有7种(P2X1~P2X7)。每个P2X受体分子由细胞内的N-端和C-端及两个跨膜结构区域组成。虽然P2X受体存在亚型及种属差异性,但是组成P2X受体的基本结构并没有明显差异,都是由3个同源或异源的亚基构成的三聚体,如P2X3为同源三聚体,P2X1/2、P2X2/3为异源三聚体(Jacobson等,Neuropharmacology,2016,31)。P2X3受体在体内分布广泛,主要表达在与伤害性信息有关的周围感觉神经元,在伤害信息的产生、传递中起着重要的介导作用。当机体受到伤害或神经损伤后释放大量ATP,与P2X3受体结合而导致受体的跨膜区域产生构象变化,从而激活P2X3受体,引起大量Ca2+内流,细胞内钙浓度增加激活蛋白激酶A、蛋白激酶C等的磷酸化,促进谷氨酸的释放和NMDA受体等的进一步激活,最终导致中枢神经敏感化。
P2X3参与多种生理病理反应,包括炎症性疼痛、神经病理性疼痛、癌性疼痛等病理性疼痛,咳嗽高血压、膀胱排尿等。比如,P2X3受体表达上调可导致痛敏形成,参与疼痛的信号传递,P2X3受体敲除后,可缓解小鼠疼痛相关行为(Cockayne DA等,Nature,2000,1011)。P2X3受体的抑制作用可以改善自发性心脏压力感受器的反射功能,有助于抑制大鼠的交感神经,从而发挥抗高血压作用(Pijacks W等,Nature Medicine,2016,1151)。P2X3受体与小鼠的排尿频率具有相关性,P2X3受体的缺失,小鼠的排尿频率也会随之降低(Gao XF等,Nature Communication,2015,7650)。人体皮肤中的ATP/P2X3信号通道与慢性瘙痒相关,所以P2X3受体抑制剂亦可用于慢性瘙痒的治疗(Chauret,N.等,49th Annual ESDR Meeting,2019)。
另有研究表明,P2X3表达于豚鼠C—fibres迷走神经中,经其激动剂ATP激活后,可刺激呼吸道中的感觉神经并引发咳嗽(Abdulqawi R等,Eur Respir J,2013)。研究发现,咳嗽高敏综合征(Cough Hypersensitivity Syndrome),即慢性咳嗽,特别是难治性慢性咳嗽,为呼吸***最常见的疾病之一,病因包括多种呼吸***疾病、环境、吸烟和药物过敏等。该类疾病严重影响患者的健康与生活质量,并受环境恶化和人口老龄化等因素的影响呈逐年递增趋势,但现有药物的治疗选择却甚少。因此,需对咳嗽机制进行研究以揭开新的治疗靶点,并开发新的治疗方法以改善患者生活质量。近年临床数据显示,P2X3受体抑制剂AF-219在降低慢性咳嗽患者的咳嗽频率与严重程度上效果显著(Abdulqawi R等,Eur RespirJ,2013,42;Abdulqawi R等,Lancet,2015,1198;Garceau D等,Pulmonary Pharmacology&Therapeutics,2019,56;Muccino D等,Pulmonary Pharmacology&Therapeutics,2019,75)。
但与此同时,临床试验亦表明,AF-219通过影响舌头的味觉,可导致治疗对象的味觉紊乱(Abdulqawi等,Lancet 2015)。这种副作用归因于P2X2/3通道(P2X2和P2X3亚型的异源三聚体)的阻塞(Cockayne,D.A.等,J.Physiol.2005,621;Pulmonary Pharmacology&Therapeutics,2019)。因此,开发具有P2X3亚型受体选择性的拮抗剂可解决此类慢性病治疗期间的病人依从性不足的问题。本发明所述的具有新型化合物结构的P2X3抑制剂在选择性、药代动力学和药效学等方面具有出人意料且有利的性质,可以很大程度上拓展P2X3靶向药物的研发,这构成了本发明的基础。
发明内容
本发明提供了一种新型的作为配体门控非选择性阳离子通道受体亚型P2X3抑制剂的N-甲酰胺基吡唑啉类衍生物。
本发明同时公开了上述N-甲酰胺基吡唑啉类衍生物的应用。
一种N-甲酰胺基吡唑啉类衍生物,具有通式(I)所示的化合物结构或其对映异构体、非对映异构体、差向异构体、外消旋体,或其在药学上可接受的盐:
其中:
Ar选自取代或无取代苯基、包含1-3个选自O、N和S原子的取代或无取代五元杂芳环基或包含1-2个N原子的取代或无取代六元杂芳环基;当Ar选自邻位双取代苯基时,两个邻位取代基相互独立或者成环;
R1选自取代或未取代苯基或取代或未取代吡啶基;R2选自甲基、乙基、异丙基、环丙基;
R3,R4分别各自独立的选自H、C1~C5烷基、C1~C5烷氧羰基、取代或未取代的C1~C5酰基;或R3、R4连同它们两者所连接的N一起形成取代或未取代的C5~C6杂环烷基或C5~C6杂环烷基酮或C5~C6杂芳基;所述杂环烷基或杂环烷基酮环上的碳原子可进一步被一个或多个O、N取代。
所述Ar选自下列取代苯基、取代的五元或六元杂芳环基:
所述R5,R6相同或不同或缺失,分别独立选自H、卤素、硝基、氰基、甲基、三氟甲基、三氟甲氧基、甲氧基、二氧亚甲基、C1-C3直链或支链烷氧基,且在任意环碳原子上取代;选择所述二氧亚甲基时,所述R5,R6为其中的氧原子,与相连的亚甲基成环;
R7选自甲基、乙基、异丙基、环丙基。
所述卤素包括F、Cl、Br。
本发明中,所述C1~C5烷基包括甲基、乙基、丙基、异丙基、丁基、叔丁基等;所述C1~C5烷氧羰基包括甲基、乙基、丙基、异丙基、丁基、叔丁基等连接的氧羰基。所述C1~C5酰基包括甲基、乙基、丙基、异丙基、丁基、叔丁基等连接的酰基。所述C1-C3直链或支链烷氧基包括甲氧基、乙氧基、丙氧基或者异丙基氧基等。
作为优选,所述R1中,苯基或吡啶基环上的取代基选自卤素、C1-C3直链或支链烷基(包括甲基、乙基、丙基、异丙基等)、C1-C3直链或支链烷氧基、三氟甲基、三氟甲氧基。
作为优选,R3,R4分别各自独立的选自H、甲基、乙基、甲氧羰基、乙氧羰基、丙氧羰基、异丙氧羰基、叔丁氧羰基、甲酰基、乙酰基、N,N-二烷基乙酰基;或R3、R4连同它们这两者所连接的N一起形成取代或未取代吗啉酮基、取代或未取代吗啉基、取代或未取代哌啶基、取代或未取代哌嗪基、取代或未取代哌嗪酮基、取代或未取代吡咯烷酮基、取代或未取代恶唑烷酮基、取代或未取代咪唑烷酮基、取代或未取代咪唑基、取代或未取代吡唑基、1,2,3-三氮唑基、1,2,4-三氮唑基。
作为进一步优选,所述吗啉酮基、吗啉基、哌啶基、哌嗪基、哌嗪酮基、吡咯烷酮基、恶唑烷酮基、咪唑烷酮基、咪唑基、吡唑基上的取代基选自C1-C3直链或支链烷基、甲酰基、乙酰基、C1-C5直链或支链烷氧基(包括甲基、乙基、丙基、异丙基、丁基、叔丁基连接的氧基取代基)。
除非另有说明,本文所述被任选取代的成分可以在任何化学上可能的位置被取代。
作为优选,其具有通式(Ia)、(Ib)、(Ic)或(Id)所示的结构或其对映异构体、非对映异构体、外消旋体、或其在药学上可接受的盐:
作为优选,所述Ar选自苯基对三氟甲基苯基、二甲氧基苯基、二氧五环苯基、对氰基苯基、氯代苯基、甲氧基吡啶基、三氟甲基吡啶基、氯取代吡啶基、二氟吡啶基、三氟甲氧基吡啶基、三氟甲基吡嗪基、甲基吡嗪基、氯代吡嗪基、甲氧基哒嗪基、三氟甲基哒嗪基、氯代哒嗪基、三氟甲基嘧啶基、甲基嘧啶基、氯代嘧啶基、甲基-1,2,4-恶二唑基、甲基-1,3,4-恶二唑基;R1选自对甲基苯基、对甲氧基苯基、对氟苯基、对氯苯基、甲基吡啶基;R2选自甲基、乙基;R3,R4分别各自独立的选自H、甲基、乙基、甲氧羰基、乙氧羰基、乙酰基、N,N-二烷基乙酰基;或R3、R4连同它们这两者所连接的N一起形成吗啉酮基、哌嗪酮基、N-甲基哌嗪酮基、甲基哌嗪酮基、吡咯烷酮基、恶唑烷酮基、咪唑烷酮基、乙酰基咪唑烷酮基、吗啉基、哌嗪基、N-乙酰基哌嗪基、吡唑基。
更具体地,本发明通式(I)化合物中,优选的化合物包括但不限于:
本发明的另一个目的是提供一种药物组合物,所述药物组合物包含至少一种活性组分以及一种或多种药学上可接受的载体或赋形剂,所述的活性组分可以是本发明的N-甲酰胺基吡唑啉类衍生物及其在药学上可接受的盐、所述化合物的异构体、对映异构体、非对映异构体、外消旋体中的任意一种或任意多种;所述的盐选用药用上接受的无机酸盐、有机酸盐;所述的无机酸盐包括与氢卤酸,硝酸,碳酸,硫酸,磷酸形成的盐;所述的有机酸盐包括与苹果酸、L-苹果酸、D-苹果酸、枸橼酸、富马酸、草酸、乳酸、樟脑磺酸、L-樟脑磺酸、D-樟脑磺酸、对甲苯磺酸、甲磺酸、苯甲酸形成的盐;所述氢卤酸选用氢氟酸、氢溴酸、氢碘酸、盐酸。
所述载体或赋形剂包括药学领域的常规填充剂,稀释剂,湿润剂,润滑剂,粘合剂,崩解剂,吸收促进剂,表面活性剂,吸附载体,抗氧化剂、乳化剂、金属螯合剂、pH调节剂等,必要时还可以加入香味剂,甜味剂等。本发明药物可以制成片剂、胶囊、吸入剂、乳剂、混悬剂、凝胶剂、粉剂、颗粒剂、口服液及注射剂等多种形式,上述各剂型的药物均可以按照药学领域的常规方法制备。
本发明还提供通式(I)所述的任一项化合物、及其药学上可接受的盐单独和/或与其他药物联合使用在制备P2X3抑制剂中的应用,特别是在制备治疗由P2X3介导的疾病中的应用。所述的由P2X3介导的疾病包括呼吸***疾病,如慢性阻塞性肺疾病(COPD)、哮喘、急性/亚急性及慢性咳嗽、支气管痉挛;由多种原因造成的疼痛,如手术疼痛、炎性疼痛、癌性疼痛、膀胱疼痛、子宫内膜异位症疼痛、糖尿病性神经痛、创伤性疼痛、牙痛、偏头痛、及与肠易激综合征有关的疼痛;皮肤疾病如慢性瘙痒。
本发明具有通式(I)的化合物的制备可以通过以下步骤实现:
相应的取代N-甲酰氯基吡唑啉在碱性条件下与取代芳甲胺或取代杂芳甲胺缩合制得标题分子。其中,当选用手性分子R-取代芳甲胺或R-取代杂芳甲胺为合成子时,所得目标分子为差向异构体混合物,其可经柱层析梯度分离获得S,R-异构体和R,R-异构体,所用洗脱剂为石油醚:乙酸乙酯=3:1~1:3(v/v)或甲醇:乙酸乙酯=1:3~1:6(v/v);当选用手性分子S-取代芳甲胺或S-取代杂芳甲胺为合成子时,所得目标分子可经柱层析梯度分离获得S,S-异构体和R,S-异构体,所用洗脱剂为石油醚:乙酸乙酯=4:1~1:3(v/v)或甲醇:乙酸乙酯=1:3~1:6(v/v);标题化合物的立体构型分别经COSY相关谱、NOSEY谱确证。
其中:
中间体取代N-甲酰氯基吡唑啉的制备可以相应的氨基酮为原料,在碱性条件下与甲醛反应生成烯酮,再与肼反应得环合物吡唑啉,吡唑啉进而与三光气反应制得取代N-甲酰氯基吡唑啉;
中间体R-取代芳甲胺、R-取代杂芳甲胺,或S-取代芳甲胺、S-取代杂芳甲胺的制备可以相应的芳醛为原料,与S-叔丁基亚磺酰胺或R-叔丁基亚磺酰胺反应制得亚胺,进而与相应的格氏试剂或烷基锂在低温条件下经加成,水解制得R-取代芳甲胺或S-取代杂芳甲胺。
本发明通过实验证实,本发明中的化合物可选择性抑制P2X3通道活性,可应用于治疗由P2X3介导的疾病的药物中。本发明提供的抑制剂还包括该化合物的药物组合物。
附图说明
图1为标题化合物1的化学结构(A)、3D模拟图(B)、1HNMR(C)。
图2为标题化合物1的的NOESY谱。
图3为化合物1a的化学结构(A)、3D模拟图(B)、1HNMR(C)。
图4为化合物1a的NOESY谱(D)。
图5为标题化合物对ATP/枸橼酸诱导的豚鼠咳嗽的抑制作用(腹腔注射)。
图6为标题化合物对ATP/枸橼酸诱导的豚鼠咳嗽的抑制作用(口服给药)。
图7为标题各组实验动物给药后的饮水及饮用奎宁水的百分比情况。
图8为标题化合物4在人工胃肠液中的降解剩余百分率。
图9为标题化合物22在人工胃肠液中的降解剩余百分率。
具体实施方式
本发明结合实施例作进一步的说明,以下实施例仅是具体地说明本发明,而不是以任何方式限制本发明。此外,关于本实施例中使用的原料、中间体、试剂等,若没有特别记载,则是在本领域按照通常实施的方法制备得到、或者是可通过商业购买得到。
一、主要中间体的制备方法
1.中间体N-甲酰氯基吡唑啉衍生物(A)的制备
1).4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑-1-甲酰氯(A-1)的合成
步骤1.N-甲基-N-(2-氧代-2-(4-甲基苯基)乙基)乙酰胺(A-1a)的合成
将30%甲胺醇溶液(7.29g,70.41mmol)加入至乙腈(20mL)中,N2保护下,降温至-15℃~-10℃,慢慢滴加4-甲基-α-溴代苯乙酮(5g,23.47mmol)的乙腈(40mL)溶液,滴加完毕,维持-15℃~-10℃搅拌20min。将反应液升温至-5℃~0℃,滴加冰水(60mL),搅拌5min,加入乙酸乙酯(30mL),搅拌5min,静置分层,水相用乙酸乙酯萃取(20mL×2),合并有机相,用水洗涤两次并用无水Na2SO4干燥,过滤,向滤液中加入三乙胺(3.5g,35.2mmol),N2保护下降至-10℃~-5℃,滴加乙酰氯(3.68g,46.94mmol),继续搅拌10~20min,加水(80mL),室温搅拌10min,水相用乙酸乙酯萃取(30mL×2),合并有机相,无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析分离(PE:EA=3:1,v/v),得化合物A-1a,淡黄色固体,收率=41.5%;ESI-MS:m/z=206[M+1]+。
步骤2.N-甲基-N-(3-氧代-3-(4-甲基苯基)丙基-1-烯-2-基)乙酰胺(A-1b)的合成将化合物A-1a(2.0g,9.76mmol),37%甲醛溶液(2.38g,29.28mmol)和哌啶(0.41g,4.88mmol)加入至THF(10mL)中,加热至70~75℃搅拌5h后,再加入37%甲醛溶液(2.38g,29.28mmol)和哌啶(0.41g,4.88mmol),搅拌过夜,TLC监控至无原料,降至室温,过滤,滤液减压浓缩至干,残留物经硅胶柱层析分离(PE:EA=2:1,v/v),得化合物A-1b,收率67.0%;1H NMR(500MHz,DMSO-d6):δ7.77(d,J=7.3Hz,2H),7.35(d,J=7.4Hz,2H),5.70(d,J=2.3Hz,1H),5.28(d,J=2.2Hz,1H),3.22(s,3H),2.42(s,3H),1.95(s,3H);ESI-MS:m/z=218[M+1]+。
步骤3.4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑-1-甲酰氯(A-1)的合成
将化合物A-1b(3.0g,13.8mmol)、水合肼(1.38g,27.6mmol)、EtOH(15mL)加入至反应瓶中,N2保护,加热至80℃搅拌3h,反应液降至室温,减压蒸去乙醇,加入水(10mL),搅拌,用乙酸乙酯(15mL×2)萃取,有机相用无水Na2SO4干燥,过滤,滤液减压浓缩至干,得化合物A-1c粗品,未经进一步纯化,直接用于下一步反应。
将三光气(1.30g,4.32mmol)、二氯甲烷(20mL)加入至干燥反应瓶中,N2保护降温至-10℃,另将化合物A-1c(2.0g,8.64mmol)、吡啶(2.04g,25.80mmol)与二氯甲烷(20mL)混合,并于-10℃将混合液滴加至反应瓶中,加毕,室温搅拌10min,加入稀盐酸淬灭反应,分出有机相,水相用二氯甲烷萃取(10mL×2),合并有机相,用饱和食盐水洗涤,无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析分离(PE:EA=3:1~1:3,v/v),得化合物A-1,淡黄色固体,二步收率46%;1H NMR(500MHz,CDCl3):δ7.86(d,J=8.0Hz,2H),7.26(d,J=8.0Hz,2H),5.20-5.11(m,1H),4.02-3.87(m,2H),3.27(s,3H),2.42(s,3H),2.32(s,3H);ESI-MS:m/z=294[M+1]+。
表1.1中所列中间体A-6是使用4-氟-α-溴代苯乙酮代替4-甲基-α-溴代苯乙酮为原料,按制备化合物A-1同样的方法合成得到。
2).4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑-1-甲酰氯(A-2)的合成
步骤1.4-(3-氧代-3-(4-甲基苯基)丙基-1-烯-2-基)吗啉-3-酮(A-2a)的合成
将4-(2-氧代-2-(4-甲基苯基)乙基)吗啉-3-酮(10.0g,42.9mmol)、多聚甲醛(3.8g,128.7mmol)和哌啶(1.8g,21.5mmol)加入至THF(100mL)中,在70~75℃下搅拌5h后,再加入多聚甲醛(3.8g,128.7mmol)和哌啶(1.8g,21.5mmol),搅拌过夜,TLC监控至无原料,降至室温,过滤,滤液减压浓缩至干,残留物经硅胶柱层析分离(PE:EA=3:1,v/v),得化合物A-2a,收率88.0%;1HNMR(500MHz,DMSO-d6):δ7.67(d,J=7.5Hz,2H),7.55(d,J=7.5Hz,2H),5.70(d,J=2.1Hz,1H),5.24(d,J=2.1Hz,1H),4.21(s,2H),3.56(m,2H),3.37(m,2H),2.41(s,3H);ESI-MS:m/z=246[M+1]+。
步骤2.4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑-1-甲酰氯(A-2)的合成
将化合物A-2a(5.0g,20.4mmol)、水合肼(2.05g,40.75mmol)加入至EtOH(25mL)中,N2保护下在80~82℃搅拌3h,TLC监控至无原料,降至室温,减压蒸去体系中乙醇,加入水,搅拌,用乙酸乙酯萃取,有机相用无水Na2SO4干燥,过滤,滤液减压浓缩至干,得化合物A-2b粗品,未经进一步纯化,直接用于下一步反应。
将三光气(1.71g,5.76mmol)、二氯甲烷(30mL)加入至干燥反应瓶中,N2保护下降至-10℃~-5℃,将化合物A-2b(3.0g,11.55mmol)、吡啶(2.7g,34.2mmol)加入至二氯甲烷(30mL)中,并于-10℃~-5℃滴加至反应瓶中,滴加完毕,于室温下搅拌10min,加入稀盐酸淬灭反应,分出有机层,水相用二氯甲烷萃取(10mL×2),合并有机相,有机相用饱和食盐水洗涤,用无水Na2SO4干燥,过滤,滤液减压浓缩至干,经硅胶柱层析分离(PE:EA=4:1~1:1,v/v),得中间体化合物A-2,淡黄色固体,二步收率56%;1H NMR(500MHz,CDCl3):δ7.72(d,J=8.0Hz,2H),7.25(d,J=8.0Hz,2H),6.61-6.57(m,1H),4.29-4.17(m,2H),4.03-3.94(m,2H),3.78-3.67(m,2H),3.21-2.93(m,2H),2.39(s,3H);ESI-MS:m/z=322[M+1]+。
表1.1中所列化合物A-7~A-14是使用相应的取代吗啉酮或取代吗啉或取代哌嗪或取代哌嗪酮(A-7:4-(2-氧代-2-(4-氟苯基)乙基)吗啉-3-酮;A-8:4-(2-氧代-2-(4-氯苯基)乙基)吗啉-3-酮;A-9:4-(2-氧代-2-(4-甲氧基苯基)乙基)吗啉-3-酮;A-10:4-(2-氧代-2-(4-氟苯基)乙基)吗啉;A-11:4-乙酰基-1-(2-氧代-2-(4-甲基苯基)乙基)哌嗪;A-12:4-甲基-1-(2-氧代-2-(4-甲基苯基)乙基)哌嗪;A-13:4-甲基-1-(2-氧代-2-(4-甲基苯基)乙基)哌嗪-2-酮;A-14:4-(2-氧代-2-(4-甲基苯基)乙基)吗啉)替代4-(2-氧代-2-(4-甲基苯基)乙基)吗啉-3-酮为原料,按制备化合物A-2同样的方法合成得到。
3).4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑-1-甲酰氯(A-3)的合成
步骤1.1-(3-(4-甲基苯基)-4,5-二氢-1H-吡唑-4-基)吡咯烷-2-酮(A-3a)的合成将1-(2-氧代-2-(4-甲基苯基)乙基)吡咯烷-2-酮(5.0g,23.01mmol)和37%甲醛溶液(2.70mL,33.2mmol)溶于二氧六环(50mL)中,滴加哌啶(2.83g,33.2mmol),加毕,在105℃下搅拌6h,降至室温,减压蒸去二氧六环。向体系中加入45mL乙酸乙酯,50mL饱和食盐水,搅拌5min,静置分层,水相用乙酸乙酯(20mL)萃取,合并有机相,无水Na2SO4干燥,过滤,滤液减压浓缩至干,得黄色油状物。将上述黄色油状物溶于乙醇(120mL)中,加入水合肼(4.16g,66.5mmol),混合物于70℃~80℃加热搅拌反应3hr,冷至室温,减压蒸除去溶剂,残留物中加THF(30mL)和水(10mL),室温搅拌,过滤,滤饼用少量THF洗二次,固体物真空干燥,得化合物A-3a,收率65%;1HNMR(500MHz,DMSO-d6):δ9.15(brs,1H),7.70(d,J=7.4Hz,2H),7.30(d,J=7.4Hz,2H),4.51(m,1H),3.30-3.04(m,4H),2.42(s,3H),2.24(m,2H),1.95(m,2H);ESI-MS:m/z=244[M+1]+。
步骤2.4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑-1-甲酰氯(A-3)的合成
将三光气(1.55g,5.14mmol)、无水二氯甲烷(25mL)加入至干燥反应瓶中,N2保护,降温至-8℃~-10℃,另将化合物A-3a(2.5g,10.28mmol)、吡啶(2.65g,22.54mmol)溶于二氯甲烷(25mL)中,并于-10℃滴加至反应瓶中,滴加毕,室温搅拌10min,加入稀盐酸淬灭反应,分出有机相,水相用二氯甲烷萃取(10mL×2),合并有机相,用饱和食盐水洗涤,无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析分离(PE:EA=4:1~1:2,v/v),得化合物A-3,淡黄色固体,收率66%;1HNMR(500MHz,CDCl3):δ7.78(d,J=8.0Hz,2H),7.21(d,J=8.0Hz,2H),5.10-4.86(m,1H),3.65-3.54(m,2H),3.29-3.20(m,2H),2.42(s,3H),2.35-2.27(m,2H),1.99-1.91(m,2H);ESI-MS:m/z=306[M+1]+。
表1.1中所列化合物A-15,A-16,A-18~A-21是使用相应的原料(A-15:1-(2-氧代-2-(4-氟苯基)乙基)吡咯烷-2-酮;A-16:3-(2-氧代-2-(4-甲基苯基)乙基)恶唑烷-2-酮;A-18:3-(2-氧代-2-(4-氯苯基)乙基)恶唑烷-2-酮;A-19:1-(2-氧代-2-(4-甲基苯基)乙基)-3-甲基咪唑烷-2-酮;A-20:1-(2-氧代-2-(4-甲基苯基)乙基)-3-乙酰基咪唑烷-2-酮;A-21:1-(2-氧代-2-(5-甲基吡啶-2-基)乙基)吡咯烷-2-酮)替代1-(2-氧代-2-(4-甲基苯基)乙基吡咯烷-2-酮),按制备化合物A-3同样的方法合成得到。
4).4-(N-甲基-N-叔丁氧羰基胺基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑-1-甲酰氯(A-4)的合成
步骤1.N-甲基-N-(2-氧代-2-(4-甲基苯基)乙基)氨基甲酸叔丁酯(A-4a)的合成
将30%甲胺醇溶液(11.5mL,70.41mmol)、乙腈(20mL)加入至反应瓶中,N2保护下降温至-15℃~-10℃,慢慢滴加4-甲基-α-溴代苯乙酮(5g,23.47mmol)的乙腈(40mL)溶液,滴加完毕,保温搅拌20min。将反应体系升温至-5℃~0℃,滴加冰水(60mL),搅拌5min,加入乙酸乙酯(30mL),搅拌5min,静置分层,水相用乙酸乙酯萃取(20mL×2),合并有机相,有机相用水洗涤两次,无水Na2SO4干燥,过滤,向滤液中加入三乙胺(4.8mL,35.2mmol),N2保护下降至-10℃~-5℃,滴加(Boc)2O(7.68g,35.21mmol),加毕,室温搅拌30min,加入水(80mL),室温下继续搅拌10min,静置分层,水相用乙酸乙酯萃取(20mL×2),合并有机相,用无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析分离(PE:EA=3:1~1:1,v/v),得化合物A-4a,淡黄色固体,收率63.9%;ESI-MS:m/z=264[M+1]+。
步骤2.N-甲基-N-(3-氧代-3-(4-甲基苯基)丙基-1-烯-2-基)氨基甲酸叔丁酯(A-4b)的合成
将化合物A-4a(3.5g,13.29mmol),37%甲醛溶液(3.0mL,39.87mmol)和哌啶(0.6mL,6.65mmol)加入至二氧六环(30mL)中,在105℃下搅拌6h,TLC监控至无原料,降至室温,减压蒸去二氧六环。向体系中加入15mL乙酸乙酯,30mL饱和食盐水,搅拌5min,静置分层,水相用乙酸乙酯(15mL)萃取一次,合并有机相,用无水Na2SO4干燥,过滤,滤液减压浓缩至干,即得化合物A-4b粗品,黄色油状,收率65%,无需进一步精制,可直接用于下一步反应。
步骤3.4-(N-甲基-N-叔丁氧羰基胺基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑(A-4c)的合成
将化合物A-4b(5.12g,18.6mmol)、水合肼(1.0mL,19.98mmol)加入至乙醇(40mL)中,N2保护,加热至85℃搅拌3h,降至室温,减压蒸去乙醇,残留物中加入水(10mL),搅拌,用乙酸乙酯萃取(2×20mL),合并有机相,用无水Na2SO4干燥,过滤,滤液减压浓缩至干,得化合物A-4c粗品,黄色油状物,收率68%,无需进一步精制,可直接用于下一步反应。
步骤4.4-(N-甲基-N-叔丁氧羰基胺基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑-1-甲酰氯(A-4)的合成
将三光气(1.97g,6.65mmol)、干燥二氯甲烷(30mL)加入至三口瓶中,N2保护下降至-10℃,将含化合物A-4c(6.07g,21.0mmol)、吡啶(3.4mL,39.87mmol)的二氯甲烷(30mL)慢慢滴加至上述三口瓶中,加毕,于室温搅拌10min,加水淬灭反应,分离有机层,水相用二氯甲烷萃取(2×20mL),合并有机相,用饱和食盐水洗涤,无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析分离(PE:EA=3:1~1:1,v/v),得中间体A-4,淡黄色固体,收率76%;1HNMR(500MHz,CDCl3):δ7.82(d,J=7.8Hz,2H),7.31(d,J=8.0Hz,2H),4.68(m,1H),3.60=3.47(m,2H),3.27(s,3H),2.41(s,3H),1.41(s,9H);ESI-MS:m/z=352[M+1]+。
表1.1中所列中间体A-17是使用4-甲氧基-α-溴代苯乙酮代替4-甲基-α-溴代苯乙酮为原料,按制备化合物A-4同样的方法合成得到。
5).4-(吡唑-1-基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑-1-甲酰氯(A-5)的合成
步骤1.2-(1H-吡唑-1-基)-1-(4-甲基苯基)丙-2-烯-1-酮(A-5a)的合成
将2-(吡唑-1-基)-1-(4-甲基苯基)乙基-1-酮(10.02g,50mmol)和甲醇20mL分别加入反应瓶中,搅拌下加入37%甲醛水溶液(20mL,250mmol),哌啶(2.5g,30mmol)及冰醋酸2.8mL,室温搅拌反应约5hr,用TLC检测反应终点,反应毕,用乙酸乙酯(100mL×2)提取,乙酸乙酯层用饱和食盐水洗涤,无水Na2SO4干燥,过滤,滤液减压回收乙酸乙酯,得化合物A-5a,淡黄色油状物,收率66%,不经进一步纯化,直接用于下步反应。
步骤2.4-(吡唑-1-基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑(A-5b)的合成
将化合物A-5a(6.5g,30mmol)溶于乙醇70mL中,搅拌下加入水合肼(3g,60mmol),加热至45℃~50℃反应40min,减压蒸除乙醇,残留物用二氯甲烷(50mL×2)提取,饱和食盐水洗涤,无水Na2SO4干燥,过滤,残留物用乙酸乙酯/石油醚重结晶,得化合物A-5b,类白色固体,收率62%;ESI-MS:m/z=227[M+1]+。
步骤3.4-(吡唑-1-基)-3-(4-甲基苯基)-4,5-二氢-1H-吡唑-1-甲酰氯(A-5)的合成
将三光气(2.75g,9.09mmol)、无水二氯甲烷(45mL)加入至干燥反应瓶中,N2保护降温至-15℃~-10℃,另将化合物A-5b(4.0g,18.2mmol)、吡啶(4.7g,39.9mmol)溶于二氯甲烷(45mL)中,并于-15℃~-10℃滴加至反应瓶中,滴加毕,室温搅拌10min,加入稀盐酸淬灭反应,分出有机相,水相用二氯甲烷萃取(20mL×2),合并有机相,用饱和食盐水洗涤,无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱分离(PE:EA=3:1~1.5:1,v/v),得-化合物A-5,淡黄色固体,收率56%;1HNMR(500MHz,CDCl3):δ7.83(d,J=7.5Hz,1H),7.68(d,J=8.0Hz,2H),7.30(d,J=7.5Hz,1H),7.21(d,J=8.0Hz,2H),6.40-6.33(m,1H),6.25-6.22(m,1H),3.81-3.56(m,2H),2.43(s,3H);ESI-MS:m/z=289[M+1]+。
表1.1中间体A-6~A-21的结构与质谱数据
2.中间体手性-α-取代-芳基/杂芳基甲胺衍生物(B)的制备
1).(R)-1-(4-(三氟甲基)苯基)乙烷-1-胺(B-1)的合成
步骤1.(E)-2-甲基-N-(4-(三氟甲基)苯亚甲基)丙基-2-亚磺酰胺(B-1a)的合成
将4-三氟甲基苯甲醛(5.0g,28.7mmol)、S-叔丁基亚磺酰胺(3.80g,31.7mmol)、无水硫酸铜(9.16g,57.4mmol)加入至二氯甲烷(70mL)中,50℃保温搅拌18~20h,TLC监控至无原料,降至室温,过滤,滤液减压浓缩,残留物经硅胶柱层析(PE:EA=5:1~1:1,v/v)分离,得化合物B-1a,白色固体,收率76.6%。ESI-MS:m/z=278[M+1]+。
步骤2.N-((R)-1-(4-(三氟甲基)苯基)乙基)-2-甲基-丙基-2-亚磺酰胺(B-1b)的合成
将化合物B-1a(5.0g,18.03mmol)、甲苯(80mL)加入至三口瓶中,N2保护下降温至-70℃,将甲基锂(1.6M***溶液10.2mL,16.3mmol)缓慢滴加至三口瓶中,并维持-78℃搅拌反应1h,加入饱和氯化铵(50mL)淬灭反应并室温搅拌10min,静置,分层,水相用二氯甲烷萃取三次,合并有机相,有机相用无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析(PE:EA=3:1~1:3,v/v)分离,得化合物B-1b,白色固体,收率52.2%。ESI-MS:m/z=294[M+1]+。
步骤3.(R)-1-(4-(三氟甲基)苯基)乙烷-1-胺(B-1)的合成
将化合物B-1b(2.0g,6.8mmol)、甲醇(30mL)加入至100mL反应瓶中,室温下滴加4.0M HCl的二氧六环液6mL(24mmol),继续室温搅拌1h,压减回收溶剂,残留物中加入10ml碳酸钾水溶液,搅拌10min后,用二氯甲烷-甲醇混合液(10:1)萃取四次,减压回收溶剂,得化合物B-1,淡黄色油状物,收率71.3%。ee值:99%(HPLC,Chiralpak AD-3柱,检测条件:已烷/异丙醇=93/7,流速=0.8mL/min,uv-vis检测器);1HNMR(400MHz,CDCl3):δ8.77(brs,2H),7.54(m,2H),7.21(m,2H),4.01(m,1H),1.27(d,J=6.8Hz,3H);ESI-MS:m/z=190[M+1]+。
表1.2中所列中间体B-2~B-5是使用相应的取代芳醛(B-2:4-氯苯甲醛;B-3:3,4-二甲氧基苯甲醛;B-4:4-氰基苯甲醛;B-5:3,4-亚甲基二氧苯甲醛)为原料代替4-三氟甲基苯甲醛,按制备化合物B-1同样的方法合成得到。
2).(R)-1-(2-(三氟甲基)嘧啶-5-基)乙烷-1-胺(B-6)的合成
步骤1.(E)-2-甲基-N-((2-(三氟甲基)嘧啶-5-基)亚甲基)丙基-2-亚磺酰胺(B-6a)的合成
将2-三氟甲基嘧啶-5-甲醛(5g,28.4mmol)、S-叔丁基亚磺酰胺(3.79g,31.3mmol)、无水硫酸铜(9.06g,56.8mmol)加入至二氯甲烷(70mL)中,50℃保温搅拌18~20h,TLC监控至无原料,降至室温,过滤,滤液减压浓缩,残留物经硅胶柱层析(PE:EA=5:1~1:1,v/v)分离,得化合物B-6a,白色固体,收率70%。ESI-MS:m/z=280[M+1]+。
步骤2.N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-2-甲基-丙基-2-亚磺酰胺(B-6b)的合成
将化合物B-6a(4.0g,14.3mmol)、干燥二氯甲烷(80mL)加入至三口瓶中,N2保护下降温至-78℃,将甲基溴化镁(3.0M的四氢呋喃溶液10.5mL,31.5mmol)缓慢滴加至三口瓶中,并维持-78℃~-70℃搅拌反应2.5h,然后升温至-40℃继续搅拌反应2h后,加入饱和氯化铵(50mL)淬灭反应,室温搅拌10min,静置,分层,水相用二氯甲烷萃取三次,合并有机相,有机相用无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析(PE:EA=3:1~1:3,v/v)分离,得化合物B-16b,白色固体,收率45%。ESI-MS:m/z=296[M+1]+。
步骤3.(R)-1-(2-(三氟甲基)嘧啶-5-基)乙烷-1-胺(B-6)的合成
将化合物B-6b(1.2g,4.06mmol)、甲醇(20mL)加入至100mL反应瓶中,室温下将HCl(4.0M的二氧六环溶液;5mL,20mmol)滴加至反应瓶中,室温搅拌1h,TLC检测原料消失。减压回收溶剂,加入10mL碳酸钾水溶液,搅拌10min后,用二氯甲烷:MeOH(10:1)萃取四次,减压回收溶剂,得化合物B-6,淡黄色油状物,收率80%。ee值:99%(HPLC,Chiralpak AD-3柱,检测条件:已烷/异丙醇=93/7,流速=0.8mL/min,uv-vis检测器);1HNMR(500MHz,CDCl3):δ8.85(s,2H),8.77(brs,1H),4.91-4.85(m,1H),1.67(d,J=7.0Hz,3H);ESI-MS:m/z=192[M+1]+。
表1.2中所列中间体B-7~B-22是使用相应的取代杂芳醛(B-7:2-甲基嘧啶-5-甲醛;B-8:2-氯嘧啶-5-甲醛;B-9、B-21:6-三氟甲基吡啶-3-甲醛;B-10:6-甲氧基吡啶-3-甲醛;B-11:6-三氟甲氧基吡啶-3-甲醛;B-12:5,6-二氟吡啶-3-甲醛;B-13:6-氯吡啶-3-甲醛;B-14:5-三氟甲基吡啶-2-甲醛;B-15:5-甲氧基吡啶-2-甲醛;B-16:5-三氟甲基哌嗪-2-甲醛;B-17:5-甲基哌嗪-2-甲醛;B-18:6-三氟甲基哒嗪-3-甲醛;B-19:6-氯哒嗪-3-甲醛;B-20:2-三氟甲基嘧啶-5-甲醛;B-22:6-甲氧基哒嗪-3-甲醛)为原料替代2-三氟甲基嘧啶-5-甲醛,按制备化合物B-6同样的方法合成得到。其中,中间体B-20,B-21的制备采用R-叔丁基亚磺酰胺为手性源试剂。
表1.2中间体B-2~B-22的结构与质谱数据
二、标题化合物的制备实例
制备实施例1.(S)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(化合物1)和差向异构体1a的合成
合成步骤:将化合物A-2(1.05g,3.26mmol)、化合物B-9(0.62g,3.26mmol)加入至二氯甲烷(10mL)中,再加入N,N-二异丙基乙胺(DIPEA,1.26g,9.75mmol),室温搅拌过夜,加入0.5N盐酸(10mL)搅拌10min。静置分层,分出有机相,水相用二氯甲烷(10mL×3)萃取,合并有机相,用无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析梯度分离(PE:EA=3:1~1:3,v/v)得标题化合物1,收率32%和它的R,R-差向异构体1a,收率29%。
标题化合物1与其差向异构体1a的结构和1H-NMR核磁谱见图1和图3,标题化合物1与其差向异构体1a的立体结构解析(图2,图4):
1)鉴于标题化合物1的合成中,中间体B-9为R-型手性合成子,而另一合成子A-2为消旋体,且标题化合物1与1a的质谱数据均为ESI-MS:m/z=476[M+H]+,同时,二者氢质子数相同,故互为差向异构体;
2)根据标题化合物11H-NMR(400MHz,CDCl3)的氢质子化学位移及1H-1HCOSY谱对标题化合物1氢质子各信号进行归属:
δ8.74(s,1H,H-16),7.86(d,J=7.9Hz,1H,H-17),7.64(d,J=8.0Hz,1H,H-18),7.62(d,J=8.0Hz,2H,H-5H-6),7.21(d,J=7.9Hz,2H,H-3H-4),6.60(dd,J=11.0,3.7Hz,1H,H-9),6.34(d,J=7.0Hz,1H,H-19),5.14(brs,1H,H-15),4.23-4.13(m,2H,H-13),4.00(t,J=12.0Hz,1H,H-10a),3.96(dd,J=12.9,3.7Hz,1H,H-10b),3.78(m,1H,H-12a),3.67(m,1H,H-12b),3.22(m,1H,H-11a),2.95(m,1H,H-11b),2.37(s,3H,H-1),1.64(d,J=7.0Hz,3H,H-14);
化合物1a氢谱各信号从低场到高场的归属顺序与标题化合物1一致。
3)根据化合物1及1a的化学结构结合三维模拟图可知,甲基苯环/吡唑啉环/碳酰胺三部分均分别基本处于同平面结构。当C-9位构型为S时,吗啉酮环与C-14位甲基同侧,NOSEY谱中显示C-14位甲基氢质子与11,13位氢质子有相关,由此确定标题化合物1结构中C-9位构型为S-型。反之,当C-9位构型为R-型时,吗啉酮环与C-14位甲基异侧,NOSEY谱中显示C-14位甲基氢质子与C-11,C-12,C-13位氢质子均无相关,由此确定化合物1a结构中C-9位构型为R-型。
制备实施例2.(S)-4-(4-甲基-2-氧代哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(4-氯苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(化合物2)和差向异构体2a的合成
合成步骤:将化合物B-2(500mg,2.63mmol)加入至二氯甲烷(5mL)中,冷却至0℃,N2保护下加入三光气(370mg,1.25mmol),Et3N(660mg,6.55mmol),升至室温搅拌1h。将反应液倒入水中,用二氯甲烷萃取(10mL×2),有机相用无水Na2SO4干燥,过滤,减压回收溶剂,得异氰酸酯粗品,未经进一步纯化,直接用于下步反应。
将化合物1-(3-(4-甲基苯基)-4,5-二氢-1H-吡唑-4-基)-4-甲基哌嗪-2-酮(500mg,1.80mmol),异氰酸酯粗品(410mg,2.27mmol),K2CO3加入到丙酮(10mL)中,N2保护,室温搅拌2h,TLC显示原料消失。将反应液倒入二氯甲烷中,水洗,饱和食盐水洗。有机相用无水Na2SO4干燥,过滤,滤液减压回收溶剂,残留物经硅胶柱层析梯度分离(MeOH:EA=1:4,v/v),得标题化合物2,白色固体,收率35%,和它的R,R-差向异构体2a,收率25%。
标题化合物2:1H NMR(400MHz,CDCl3):δ7.65(d,J=7.4Hz,2H),7.36-7.28(m,4H),7.24(d,J=7.8Hz,2H),6.68-6.60(m,1H),6.29(d,J=8.0Hz,1H),5.08(dd,J=14.3,7.4Hz,1H),4.12-3.95(m,2H),3.27-3.01(m,4H),2.83-2.47(m,2H),2.41(s,3H),2.26(s,3H),1.60(d,J=6.9Hz,3H);ESI-MS:m/z=454[M+H]+。
差向异构体2a:1H NMR(400MHz,CDCl3):δ7.70(d,J=7.8Hz,2H),7.46-7.42(m,4H),7.22(d,J=7.8Hz,2H),6.66-6.58(m,1H),6.32(d,J=8.0Hz,1H),5.06(dd,J=14.0,7.0Hz,1H),4.11-3.94(m,2H),3.30-3.05(m,4H),2.86-2.42(m,2H),2.42(s,3H),2.28(s,3H),1.62(d,J=7.2Hz,3H);ESI-MS:m/z=454[M+H]+。
制备实施3.(S)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(化合物3)和差向异构体3a的合成
合成步骤:将化合物A-2(1.05g,3.26mmol)、化合物B-6(0.62g,3.25mmol)加入至二氯甲烷(10mL)中,再加入N,N-二异丙基乙胺(DIPEA,1.26g,9.75mmol),室温搅拌过夜,加入0.5N盐酸10mL)搅拌10min。静置分层,分出有机相,水相用二氯甲烷(10mL×3)萃取,合并有机相,用无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析梯度分离(PE:EA=2:1~1:3,v/v)得标题化合物3,收率37%,和它的R,R-差向异构体3a,收率30%。
标题化合物3:1H NMR(500MHz,CDCl3):δ8.91(s,2H),7.62(d,J=8.2Hz,2H),7.23(d,J=8.0Hz,2H),6.62(dd,J=11.1,4.1Hz,1H),6.34(d,J=7.0Hz,1H),5.20–5.12(m,1H),4.20(m,2H),4.05(dd,J=13.0,11.1Hz,1H),3.96(dd,J=13.0,4.1Hz,1H),3.80(m,1H),3.68(m,1H),3.23(m,1H),2.94(m,1H),2.39(s,3H),1.69(d,J=7.1Hz,3H);ESI-MS:m/z=477[M+1]+。
差向异构体3a:1H NMR(500MHz,CDCl3):δ8.88(s,2H),7.70(d,J=8.0Hz,2H),7.25(d,J=8.0Hz,2H),6.60(dd,J=11.0,4.0Hz,1H),6.40(brs,1H),5.22–5.13(m,1H),4.22(m,2H),4.02(dd,J=12.2,11.0Hz,1H),3.94(dd,J=12.0,4.0Hz,1H),3.78(m,1H),3.65(m,1H),3.21(m,1H),2.92(m,1H),2.36(s,3H),1.65(d,J=7.5Hz,3H);ESI-MS:m/z=477[M+1]+。
制备实施4.(S)-4-(N-甲基-N-乙氧羰基胺基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(化合物4)的合成
步骤1.(S)-4-(N-甲基-N-叔丁氧羰基胺基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(4-a)和差向异构体4c的合成
将化合物A-4(1.0g,2.84mmol),化合物B-6(0.52g,2.70mmol)加入至二氯甲烷(10mL)中,再加入N,N-二异丙基乙胺(DIPEA,1.0g,7.75mmol),室温搅拌过夜,加入盐酸(0.5N,10mL)并搅拌10min,静置分层,水相用二氯甲烷萃取(10mL×3),合并有机相,有机相用无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析递度分离(PE:EA=2:1~1:3,v/v),得化合物4-a,收率40.7%;ESI-MS:m/z=507[M+1]+。同时得化合物4-b,收率35%;ESI-MS:m/z=507[M+1]+。
步骤2.(S)-4-(N-甲基-N-乙氧羰基胺基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(化合物4)和差向异构体4c的合成
将化合物4-a(0.73g,1.44mmol)加入至二氯甲烷(10mL)中,加入三氟乙酸(0.3mL,4.32mmol),室温搅拌1h,减压蒸去过量三氟乙酸,向反应瓶中加入二氯甲烷(10mL),三乙胺(0.8mL,5.76mmol),将反应体系降温至-10~-5℃,并在此温度下向反应中滴加氯甲酸乙酯(0.2mL,1.73mmol),加毕,升至室温搅拌1h,加水淬灭反应,分出有机层,水层用乙酸乙酯萃取(10mL×3),合併有机相,用无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析梯度分离(PE:EA=2:1~1:3,v/v),得标题化合物4,收率56%;1H NMR(400MHz,CDCl3):δ8.97(d,J=1.7Hz,2H),7.71(d,J=7.4Hz,2H),7.26(d,J=7.9Hz,2H),6.39(d,J=6.3Hz,1H),5.24–5.15(m,1H),4.22(q,J=7.0Hz,2H),4.11–4.02(m,1H),3.94(td,J=12.6,4.6Hz,1H),2.64(d,J=16.1Hz,1H),2.43(s,3H),1.72(d,J=7.5Hz,3H),1.65(s,3H),1.30(t,J=6.7Hz,3H);ESI-MS:m/z=479[M+1]+。
以化合物4b为原料,按制备标题化合物4同样的方法合成得到差向异构体4c,收率47%;1H NMR(400MHz,CDCl3):δ8.92(s,2H),7.73(d,J=7.6Hz,2H),7.28(d,J=7.4Hz,2H),6.44(br,1H),5.20–5.08(m,1H),4.58-4.51(m,1H),4.25(q,J=7.8Hz,2H),3.88(td,J=12.8,5.0Hz,1H),2.64(d,J=16.1Hz,1H),2.43(s,3H),1.74(d,J=7.6Hz,3H),1.67(s,3H),1.35(t,J=7.6Hz,3H);ESI-MS:m/z=479[M+1]+。
制备实施例5~13,18,20~25
制备实施例5~13,18,20~25中标题化合物5~13,18,20~25和它们的R,R-差向异构体是使用相应的中间体A与中间体B为原料,按制备标题化合物1同样的方法合成得到(表2)。
制备实施例14,17,19,37~39
制备实施例14,17,19,37~39中标题化合物14,17,19,37~39和它们的R,R-差向异构体是使用相应的中间体A与中间体B为原料,按制备标题化合物2同样的方法合成得到(表2)。
制备实施例26~36,40~44
制备实施例26~36,40~44中标题化合物26~36,40~44和它们的R,R-差向异构体是使用相应的中间体A与中间体B为原料,按制备标题化合物3同样的方法合成得到(表2)。
制备实施例15,16
制备实施例15,16中标题化合物15,16和它们的R,R-差向异构体是使用相应的中间体A(同时化合物15制备时:利用ClCOCH2N(CH3)2代替实施例4中ClCOOEt;化合物16制备时:利用ClCOOMe代替实施例4中ClCOOEt)与中间体B为原料,按制备标题化合物4同样的方法合成得到(表2)。
表2.标题化合物5~44的核磁及质谱数据
制备实施例45.(S)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(3-甲基-1,2,4-恶二唑-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(化合物45)以及差向异构体45a的合成
1).(R)-1-(3-甲基-1,2,4-恶二唑-5-基)乙胺(B-22)的合成
步骤1.(R)-(1-(3-甲基-1,2,4-恶二唑-5-基)乙基)氨基甲酸叔丁酯(中间体B-22a)的合成
将N-叔丁氧羰基-D-丙氨酸(10.0g,53.0mmol)溶于DMF(40mL)中,再分别加入三乙胺(22mL),N-羟基乙脒盐酸盐(4.6g,41.8mmol)和正丙基磷酸酐20mL(50%DMF溶液),搅拌下加热至100℃~110℃反应3.5h,冷至室温,加水淬灭反应,用乙酸乙酯提取(300mL×3),合併的有机层,用饱和食盐水洗3次,无水Na2SO4干燥,减压浓缩,残留物用硅胶柱层析(PE:EA=3:1,v/v)分离,得中间体化合物B-22a,收率75%;ESI-MS:m/z=228[M+1]+。
步骤2.(R)-1-(3-甲基-1,2,4-恶二唑-5-基)乙胺(B-22)的合成
将化合物B-22a5.0g中溶于乙醇(35mL)中,冷至0℃,慢慢滴加盐酸甲醇溶液(50mL),加毕,室温搅拌过夜,反应液减压浓缩,得化合物B-22盐酸盐,类白色固体,收率95%;ESI-MS:m/z=128[M+1]+。
2).(S)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(3-甲基-1,2,4-恶二唑-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(化合物45)的合成
将化合物A-3(1.0g,3.27mmol)、化合物B-22(0.53g,3.27mmol)加入至二氯甲烷(10mL)中,再加入N,N-二异丙基乙胺(DIPEA,1.27g,9.81mmol),室温搅拌过夜,加入0.5N盐酸(10mL)搅拌10min。静置分层,分出有机相,水相用二氯甲烷(10mL×3)萃取,合并有机相,用无水Na2SO4干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析梯度分离(PE:EA=2:1~1:3,v/v),得标题化合物45,收率35%。1HNMR(500MHz,CDCl3):δ7.65(d,J=8.1Hz,2H),7.22(d,J=8.0Hz,2H),6.45(d,J=7.2Hz,1H),6.04(dd,J=11.2,4.0Hz,1H),5.10(m,1H),3.99(dd,J=12.0,11.0Hz,1H),3.87(dd,J=12.0,3.8Hz,1H),3.24-3.21(m,1H),2.90-2.82(m,1H),2.39(s,3H),2.27(s,3H),2.32-2.23(m,1H),2.05-1.78(m,3H),1.66(d,J=7.1Hz,3H);ESI-MS:m/z=397[M+1]+。
差向异构体45a,收率32%。1HNMR(400MHz,CDCl3):δ7.62(d,J=7.8Hz,2H),7.21(d,J=7.6Hz,2H),6.59(dd,J=11.0,4.0Hz,1H),6.48(brs,1H),5.12(m,1H),3.99(dd,J=11.0,4.0Hz,1H),3.86(dd,J=11.0,3.8Hz,1H),3.36-3.29(m,2H),2.43(s,3H),2.34(s,3H),2.32-2.23(m,2H),2.05-1.78(m,2H),1.65(d,J=7.2Hz,3H);ESI-MS:m/z=397[M+1]+。
制备实施例46.(S)-4-(3-氧代吗啉基)-3-(4-甲基苯基)-N-((R)-1-(3-甲基-1,2,4-恶二唑-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(化合物46)和差向异构体46a的合成
合成步骤参考制备实施例45.步骤3.只是用化合物A-7和化合物B-22反应制备标题化合物46;1HNMR(500MHz,CDCl3):δ7.78(m,2H),7.35(m,2H),6.62(dd,J=11.0,3.8Hz,1H),6.55(d,J=7.2Hz,1H),5.13-5.08(m,1H),4.24-4.10(m,2H),4.06(t,J=12.0Hz,1H),3.89(dd,J=12.5,3.8Hz,1H),3.80-3.70(m,1H),3.67-3.58(m,1H),3.20-3.10(m,1H),2.90-2.82(m,1H),2.35(s,3H),1.58(d,J=7.2Hz,3H);ESI-MS:m/z=417[M+1]+。
差向异构体46a;1HNMR(400MHz,CDCl3):δ7.80(m,2H),7.37(m,2H),6.65(m,1H),6.60(dd,J=11.0,4.0Hz,1H),5.12(m,1H),4.23-4.13(m,2H),4.02(t,J=11.0Hz,1H),3.92(dd,J=11.6,3.6Hz,1H),3.79(m,1H),3.65(m,1H),3.22-3.13(m,1H),2.93(m,1H),2.37(s,3H),1.63(d,J=7.0Hz,3H);ESI-MS:m/z=417[M+1]+。
制备实施例47.(S)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((S)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(化合物47)和差向异构体47a的合成
合成步骤:将化合物A-1(1.5g,5.1mmol)、化合物B-21(0.95g,5mmol)加入至二氯甲烷(10mL)中,再加入N,N-二异丙基乙胺(DIPEA,2.0g,12.2mmol),在室温下搅拌过夜,加入盐酸(0.5N,10mL)淬灭反应,搅拌10min。静置,分层,水相用二氯甲烷(10mL)萃取三次,合并有机相,有机相用无水硫酸钠干燥,过滤,滤液减压浓缩至干,残留物经硅胶柱层析梯度分离(PE:EA=2:1~1:3,v/v),得粗品,粗品经硅胶板制备层析分离,得标题化合物47,收率25%和它的R,S-差向异构体47a,收率22%。
标题化合物47:1H NMR(400MHz,CDCl3):δ8.79(s,1H),7.90(d,J=7.0Hz,1H),7.68(d,J=8.2Hz,1H),7.62(d,J=8.0Hz,2H),7.21(d,J=8.0Hz,2H),6.62(dd,J=11.2,4.0Hz,1H),6.34(d,J=6.9Hz,1H),5.20–5.10(m,1H),4.05(t,J=12.2Hz,1H),3.83(dd,J=12.8,4.2Hz,1H),2.67(s,3H),2.38(s,3H),2.07(s,3H),1.63(d,J=6.8Hz,3H);ESI-MS:m/z=448[M+1]+。
差向异构体47a:1H NMR(400MHz,CDCl3):δ8.75(s,1H),7.87(d,J=8.1Hz,1H),7.66–7.60(m,3H),7.21(d,J=8.0Hz,2H),6.61(dd,J=11.3,4.3Hz,1H),6.34(d,J=7.4Hz,1H),5.16(t,J=7.2Hz,1H),4.06–3.98(m,1H),3.86(dd,J=12.8,4.4Hz,1H),2.71(s,3H),2.38(s,3H),2.08(s,3H),1.64(d,J=7.1Hz,3H)。
三、生物学评估
1.电生理法测定标题化合物对P2X的抑制活性
化合物对于P2X受体的IC50检测实验是采取穿孔膜片钳完成[Wang et al.(2018)Proc Natl AcadSci USA 115(19):4939–4944]。所有配置溶液所需化合物均从sigma公司购买。
1)细胞培养
细胞使用HEK293细胞系。HEK293细胞放至37℃的含5%CO2的培养箱中进行培养。在细胞生长至80%-90%密度时,进行传代。弃置原60mm培养皿中的培养基,使用灭菌过的PBS溶液清洗细胞3次后吸干溶液。加入1mL 0.25%胰酶(Gibco)消化10s,吸干胰酶后加入3mL细胞培养基重悬细胞。取0.5mL重悬液加到新的培养皿中,并将总的培养液补至5mL,轻轻晃动培养皿使细胞分布均匀后放至37℃的含5%CO2的培养箱中进行培养。
2)质粒转染
首先在35mm小培养皿中铺好处理过的玻片,加入100μL重悬细胞,再将培养基总量补至2mL。采取钙转的方法将目的基因转入HEK293细胞系。对需转染的小皿在转染前1h换液,加入2mL新鲜细胞培养液。取1.5mL EP管,加入200μL的0.25M的CaCl2溶液,加入3μg所需转染质粒,混合均匀成DNA–CaCl2溶液。再将此混合溶液缓慢加入等体积的2×HBS溶液(NaCl 140mM,Na2HPO4 1.5mM,HEPES 50mM,调节pH至6.96)中,在加入的过程中边加边使用枪头进行混合,全部加完后,轻柔吹打8-10次。静置5min后加入小皿中,轻微晃动小皿使溶液混合均匀后放置细胞培养箱中。8–10h后更换培养基。转染24-48h后进行电生理实验。
3)电生理实验
使用电极拉制仪(PP-10,Narishige),通过两步法拉制得到电生理记录电极,电极中注入內液后,入水电阻为3–5MΩ。实验时,使用含制霉菌素的高钾盐內液(K2SO4 75mM,KCl120mM,MgSO4 5mM,HEPES 10mM,使用Tris-base调节pH至7.2,过滤后使用)作为电极內液,当电极封接上细胞之后,不需要进一步吸破细胞膜,而是通过制霉菌素对细胞膜的穿孔作用,使其在细胞膜上钻孔,形成孔道。本实验使用Axon200B放大器,Digidata 1440A数模转换器,在电压钳模式下使用Clampfit记录数据。钳制电压为-60mv,采样频率为10kHz,在2kHz条件下进行滤波。
P2X3受体激动剂ATP的使用浓度为1μM,两次ATP给药间隔时间为10min,所有测试化合物包括对照品AF-219先预给2min后,再与ATP进行共给。
表3.1标题化合物对人源P2X3的抑制活性(电生理法)
*AF-219购自MedChemExpress(CAS No.1015787-98-0)
表3.2化合物对大鼠和豚鼠P2X3的抑制活性(电生理法)
表3.3标题化合物对人源P2X2/3的抑制活性(电生理法)
表3.4标题化合物对人源P2X4的抑制活性(电生理法)
4)结论:由上述检测结果可知,标题化合物对人源、鼠源P2X3有较强的抑制活性,对人源P2X2/3的抑制活性明显偏弱,而对P2X4无抑制作用,说明本发明得到的化合物对P2X3有良好选择性。
2.标题化合物对PAR-1(血小板蛋白酶激活受体)的抑制活性测定
标题化合物对人源PAR-1的抑制活性采用钙离子通量荧光法(FLIPR法)测定。其方法参见Zhong等人的文献报道[Zhong et al.J BiomolStructDyn,2017,35(13):2853]。
1)细胞培养
稳定表达人源PAR-1的HEK293/Ga15重组细胞株(HD Biosciences,Shanghai,China)在DMEM(Thermo Fisher Scientific,上海)培养液(含有10%小牛血清,800μg/mLG418))中培养。培养箱条件为37℃和含5%CO2的空气湿度。
2)化合物分析板准备
第一天,将4E+5cells/mL浓度的PAR-1细胞每孔20μL播种在384孔分析板(Corning3712)中,将细胞分析板以300rpm的速度离心1min,然后在37℃、含5%CO2的培养箱中培养24h。第二天,倾除每孔的培养液,然后每孔加入20μL的1xloading dye(2μM Fluo-8 AM in1x HBSS with 20mM HEPES,1mM Probenecid,0.025%Pluronic F-127 assay buffer)。将细胞分析板在室温培养1h。
3)样品准备
将化合物溶于100%DMSO做成10mM的贮备液,在-20℃贮存。在使用当天,将化合物贮备液在室温下解冻。将每个化合物以30μM为起始浓度,用DMEM培养液进行11个浓度点的1:3系列稀释。每个化合物做双份稀释供测试。阳性对照化合物采用SCH79797,以30μM为起始浓度进行同样稀释。
4)FLIPR测定
将细胞分析板置于FLIPR仪器(Molecular Device)内,将化合物板中的10μL化合物(3x最终浓度)加到细胞分析板上的对应孔位。10分钟后,再在每孔加入10μL的TFLLR-NH2(TFA)(终浓度为10μM),以刺激产生细胞内的钙通量信号。在激发波长470/495nm,发射波长515/575nm下连续监测Ca++依赖性萤光信号,以分析化合物的抑制活性。
5)数据分析
用FLIPR程序采集分析数据。以荧光峰值评估化合物在各浓度下的抑制(或激动)活性。用EXCEL和PRISM程序计算化合物的IC50值。
表3.5标题化合物对PAR-1的抑制活性(电生理法)
6)结论:在上述实验条件下,标题化合物对PAR-1无抑制作用。
3.标题化合物大鼠体内药代动力学实验
1)给药方式
采用SD大鼠,雌雄各半,化合物按不同剂量采用静脉注射(3mg/kg)、腹腔注射(10mg/kg)或灌胃给药(30mg/kg)。在给药后的不同时间点,采集血液到EDTA血样收集管中。通过离心分离血浆并在-20℃下保存,等待分析。
2)血样处理和LC-MS/MS分析
标准曲线和质控样本配制处理:取化合物储备液用50%甲醇水稀释成含各化合物浓度分别为20-10000ng/mL的标准工作液,60、600、6000ng/mL的质控工作液。分别取47.5μL空白大鼠血浆中加入2.50μL的标准曲线工作液和质控工作液,配置成含各化合物浓度为1.00-500.00ng/mL的标曲和浓度为3.00、30.00和300.00ng/mL的质控样本,分别加入200μL的乙腈(含内标维拉帕米5ng/mL),涡旋振荡3min后,20000rcf,4℃离心15min,取上清液进行LC-MS/MS分析。
化合物血样处理:取血浆样品5μL,加入空白大鼠血浆45μL,加入200μL的乙腈(含内标维拉帕米5ng/mL),涡旋振荡3min后,20000rcf,4℃离心15min,取上清液进行LC-MS/MS分析(色谱柱:BEH C18 2.1x50mm 1.7μm;流动相A:0.1%甲酸水;流动相B:乙腈;流速:0.35mL/min)。
表3.6标题化合物的主要药代动力学参数
3)结论:由上述实验结果可知,标题化合物有良好的口服药代动力学性质和口服生物利用度。
4.ATP/枸橼酸诱导的豚鼠咳嗽实验
采用ATP/枸橼酸诱导豚鼠咳嗽模型,观察化合物经腹腔注射和灌胃给药对豚鼠咳嗽的抑制作用[Carceau and Chauret(2019)Pulmonary Pharmacology&Therapeutics 56:56–62]。
1)实验动物
采用普通级SD豚鼠,雄性动物体重:244~320g;雌性动物体重:227~331g。豚鼠饲养于塑料笼盒中,自由摄食,自由饮水,笼盒内铺有玉米芯垫料,雌雄分笼饲养,每笼不10只。控制温度20~26℃,相对湿度为40%~70%。采用自动光照,每12h明暗交替,8:00a.m.开灯,8:00p.m.关灯。
2)动物分组和给药
根据性别及初筛时枸橼酸诱导咳嗽次数,采用分层随机法分组,每组10只。化合物按不同剂量采用腹腔注射或灌胃给药。阳性对照化合物采用AF-219。空白溶媒为5%DMSO加5%Solutol HS 0.9%氯化钠溶液。
3)实验方法
豚鼠筛选:将豚鼠置于约25cm×10cm×8cm(长、宽、高)的有机玻璃盒内,喷入20%枸橼酸溶液1min,用多道生理信号采集处理***记录10min内动物的咳嗽次数,根据豚鼠的咳嗽次数,淘汰未发生咳嗽的豚鼠,最终筛选出雌雄各35只豚鼠,分层随机法分组,进行正式试验。
4)正式试验:各组豚鼠腹腔注射给药后20min,或灌胃给药后45min,将各组豚鼠置于约25cm×10cm×8cm(长、宽、高)的有机玻璃盒内。用压力雾化器向盒内持续喷入10μM的ATP溶液2min(喷入流速0.6ml/min)。再喷入20%枸橼酸溶液1min,用多道生理信号采集处理***记录10min内动物的咳嗽次数。
5)数据统计
用Excel软件录入咳嗽次数。采用GraphPad Prism 8软件作图,SPSS 18软件进行统计分析。结果见图5和图6,将各组咳嗽次数和潜伏期时间分别作方差齐性检验。若方差齐(P>0.05)则做单因素方差分析,有显著性差别(P≤0.05),则各剂量组与对照组间做Dunnett检验;否则检验结束。若方差不齐(P≤0.05),则进行非参数检验(Kruskal-WallisH检验,即K-W H检验),如K-W H检验有统计学差异(P≤0.05),则各剂量组与对照组间做Mann-Whitney U检验,否则检验结束。
6)结论:在上述实验条件下,标题化合物经腹腔注射或灌胃给药均可明显降低实验动物的咳嗽频率。
5.大鼠味觉试验
实验目的:观察标题化合物对SD大鼠味觉的影响。
1)实验方法
1.1)动物及分组:雄性SD大鼠40只,300克/只左右。将动物随机分为4组,每组10只,各组体重相近,单笼饲养。
1.2)饮水习惯训练:各组动物每天上午8.30和下午16.30分别给正常饮水30分钟,其余时间禁水,持续5天。
1.3)给药:实验前一天晚上禁水,次日上午按以下剂量腹腔注射给予以下药物:
(1)溶剂(5%DMSO/5%Solutol HS/0.9%氯化钠溶液)10mL/kg
(2)Compound 22 10mg/kg(体积10mL/kg)
(3)Compound 4 10mg/kg(体积10mL/kg)
(4)AF-21910mg/kg(体积10mL/kg)
1.4)饮水量测量:注射后将动物放回原来的笼子,溶剂、Compound 22、Compound4、AF-219的注射时间分别在各种药物的Tmax区间,每个笼子同时放入一瓶正常饮用水,一瓶含0.3mM盐酸奎宁(Quinie)的饮水,所有动物饲养笼中两瓶水放置的左右位置一致。让动物自由饮水15分钟后,分别测量两瓶水的饮用量,精确到0.1mL。
1.5)数据统计:分别统计奎宁苦味水、自来水的饮用量和总饮水量,以及奎宁水占总饮水量的百分比,比较各组动物苦味水的饮用量,用方差分析比较各组之间的差异有无显著性。
2)实验结果
各给药组SD大鼠总饮水量与溶剂对照组比较均无显著性差异(P>0.05),而阳性对照AF-219组SD大鼠苦味水的饮用量有明显增加,表明在本试验条件下受试化合物对大鼠味觉没有明显影响(图7、表3.7)。
表3.7各组实验动物的饮水量
6.肝微粒体酶稳定性实验
1)检测方法
LC-MS/MS法,其中:液相方法采用梯度洗脱法。色谱柱:BEH C18(2.1mm×50mm,1.7μm);流速:0.35mL/min;进样体积:1μL(YS001)、3μL(睾酮);柱温:40℃;自动进样器温度:4℃;流动相组成:流动相A:0.1%甲酸水,流动相B:乙腈。质谱条件采用ESI源,正离子、多反应监测(MRM)模式进行质谱分析。
2)样品处理
取肝微粒孵育样品,加含有内标(氯雷他定1ng/mL)的乙腈溶液400μL终止反应,2500rpm涡旋混匀,4℃,20000rcf离心10min,取上清液至干净内衬管中,LC-MS/MS检测原型药物含量。
3)溶液配制
储备液的配制
给药组储备液:分别称取化合物4及化合物22粉末适量,用二甲基亚砜(DMSO)溶解,配制成10mM的给药组储备液,存于-20℃冰箱中;
睾酮储备液:称取睾酮适量,用二甲基亚砜(DMSO)溶解,配制成10mM的睾酮储备液,存于-20℃冰箱中;
内标储备液:称取氯雷他定适量,用甲醇溶解,配制成1.0mg/mL的氯雷他定储备液,存于-20℃冰箱中。
工作液的配制
给药组工作液:移取化合物4及化合物22给药组储备液适量,用甲醇配制成500μM的工作液;
睾酮工作液:移取睾酮储备液适量,用甲醇配制成500μM的工作液。
4)试验内容
代谢速率试验:取人肝微粒体,于冰上解冻融化,轻轻摇匀。移取肝微粒体加至100mM磷酸缓冲液中,再分别加入化合物4(或化合物22)给药组工作液,使微粒体浓度为0.625mg/mL,化合物4或化合物22浓度为1.25μM。移取上述溶液80μL,于37℃水浴中预孵育5min后,加入5mM的NADPH溶液20μL,37℃水浴孵育。每个代谢孵育体系样本总体积100μL,孵育体系包括终浓度为0.5mg/mL的肝微粒体蛋白、1μM的化合物4(或化合物22)和1mM的NADPH。反应在进行0、10、30、60、90min后,以4倍体积乙腈(含内标氯雷他定1ng/mL)终止反应,涡旋混匀,4℃,20000rcf下高速离心10min,取上清液进行LC-MS/MS检测。每一孵育样品平行试验三份。阳性对照为相应种属微粒体对阳性药物睾酮(1μM)的代谢样本,以4倍体积乙腈(含内标氯雷他定1ng/mL)终止反应,孵育时间点为0、30、60min。
5)数据处理
采用Analyst1.6.3软件进行数据采集,在优化积分参数后,对目标色谱峰自动积分,不允许对个别色谱峰单独积分或手动积分,计算得出保留时间和峰面积。由Analyst1.6.3采集数据,经积分处理后得到保留时间、峰面积,计算分析物与内标的峰面积比,然后使用Microsoft Office Excel二次处理,计算半衰期t1/2其清除率CLint。受试化合物剩余百分比(%Control)由非零时间点样品与零时刻样品中浓度之比计算出。将Ln(%Control)对孵育时间作图并进行线性拟合。计算受试化合物清除常数(ke,1/min)、清除半衰期(t1/2,min)以及体外内在清除率(CLint,μL/(mg·min))。t1/2=0.693/ke,CLint=ke/Cprotein(注:ke为斜率,Cprotein为蛋白浓度。)
6)结论:在上述实验条件下,标题化合物对肝微粒体酶有较好稳定性。
7.模拟胃液、模拟肠液稳定性实验
1)检测方法
LC-MS/MS法,其中:液相方法采用梯度洗脱法。色谱柱:ACQUITYBEH C18(2.1mm×50mm,1.7μm);流速:0.35mL/min;进样体积:1μL;柱温:40℃;自动进样器温度:10℃;流动相组成:流动相A:0.1%甲酸水,流动相B:乙腈。质谱条件采用ESI源,正离子、多反应监测(MRM)模式进行质谱分析。
2)样品处理
取模拟胃液、模拟肠液样品,加含有内标(氯雷他定5ng/mL)的乙腈溶液1200μL,2500rpm涡旋混匀,4℃,20000rcf离心10min,取上清液至干净内衬管中,LC-MS/MS检测原型药物含量。
3)溶液配制
工作液的配制
给药组工作液:移取化合物4及化合物22给药组储备液适量,用甲醇配制成50μM的工作液;
内标工作液:移取氯雷他定储备液适量,用乙腈配制成5ng/mL的氯雷他定工作液
模拟胃液、模拟肠液的配制
空白人工胃液:取稀盐酸3.28mL,加水160mL,摇匀使其充分溶解后,调节pH值至1.3,加水稀释定容至200mL,即为空白人工胃液。
人工胃液:取稀盐酸3.28mL,加水160mL与胃蛋白酶2g,摇匀使其充分溶解后,调节pH值至1.3,加水稀释定容至200mL,即为人工胃液。
空白人工肠液:称取磷酸二氢钾1.36g,加水100mL,使其溶解,用0.1mol/L氢氧化钠溶液调节pH值至6.8,加水定容至200mL,即为空白人工肠液。
人工肠液:称取磷酸二氢钾1.36g,加水100mL,使其溶解,用0.1mol/L氢氧化钠溶液调节pH值至6.8,另外称取2g胰蛋白酶加适量水溶解,将两液混合后,加水定容至200mL,即为空白人工肠液。
4)试验内容
取模拟胃液、模拟肠液,轻轻摇匀。移取模拟胃液、模拟肠液,分别加入化合物4(或化合物22)工作液,化合物4(或化合物22)浓度为1.25μM。移取上述溶液300μL,于37℃水浴中预孵育,于0、0.5、1、1.5、2、3、5h取样,以4倍体积乙腈(含内标氯雷他定5ng/mL),涡旋混匀,4℃,20000rcf下高速离心10min,取上清液进行LC-MS/MS检测。每一孵育样品平行试验三份。
5)数据处理
采用MassLynx V4.2软件进行数据采集,在优化积分参数后,对目标色谱峰自动积分,不允许对个别色谱峰单独积分或手动积分,计算得出保留时间和峰面积。由MassLynxV4.2采集数据,经积分处理后得到保留时间、峰面积,计算分析物与内标的峰面积比,然后使用Microsoft Office Excel二次处理,计算平均剩余百分率。
6)实验结果
在上述实验条件下,化合物4及化合物22在人工胃肠液中较稳定(图8,图9)。
Claims (14)
1.一种N-甲酰胺基吡唑啉类衍生物,其特征在于,为具有通式(I)所示结构的化合物或其对映异构体、非对映异构体、差向异构体、外消旋体,或其在药学上可接受的盐:
其中:
Ar选自取代或无取代苯基、包含1-3个选自O、N和S原子的取代或无取代五元杂芳环基或包含1-2个N原子的取代或无取代六元杂芳环基;当Ar选自邻位双取代苯基时,两个邻位取代基相互独立或者成环;
R1选自取代或未取代苯基或取代或未取代吡啶基;R2选自甲基、乙基、异丙基、环丙基;
R3,R4分别各自独立的选自H、C1~C5烷基、C1~C5烷氧羰基、取代或未取代的C1~C5酰基;或R3、R4连同它们两者所连接的N一起形成取代或未取代的C5~C6杂环烷基或C5~C6杂环烷基酮或C5~C6杂芳基;所述杂环烷基或杂环烷基酮环上的碳原子可进一步被一个或多个O、N取代。
3.根据权利要求1所述的N-甲酰胺基吡唑啉类衍生物,其特征在于,所述R1中,苯基或吡啶基环上的取代基选自卤素、C1-C3直链或支链烷基、C1-C3直链或支链烷氧基、三氟甲基、三氟甲氧基。
4.根据权利要求1所述的N-甲酰胺基吡唑啉类衍生物,其特征在于,R3,R4分别各自独立的选自H、甲基、乙基、甲氧羰基、乙氧羰基、丙氧羰基、异丙氧羰基、叔丁氧羰基、甲酰基、乙酰基、N,N-二烷基乙酰基;或R3、R4连同它们这两者所连接的N一起形成取代或未取代吗啉酮基、取代或未取代吗啉基、取代或未取代哌啶基、取代或未取代哌嗪基、取代或未取代哌嗪酮基、取代或未取代吡咯烷酮基、取代或未取代恶唑烷酮基、取代或未取代咪唑烷酮基、取代或未取代咪唑基、取代或未取代吡唑基、1,2,3-三氮唑基、1,2,4-三氮唑基。
5.根据权利要求4所述的N-甲酰胺基吡唑啉类衍生物,其特征在于,所述吗啉酮基、吗啉基、哌啶基、哌嗪基、哌嗪酮基、吡咯烷酮基、恶唑烷酮基、咪唑烷酮基、咪唑基、吡唑基上的取代基选自C1-C3直链或支链烷基、甲酰基、乙酰基、C1-C5直链或支链烷氧基。
7.根据权利要求6所述的N-甲酰胺基吡唑啉类衍生物,其特征在于,所述Ar选自苯基、对三氟甲基苯基、二甲氧基苯基、二氧五环苯基、对氰基苯基、氯代苯基、甲氧基吡啶基、三氟甲基吡啶基、氯代吡啶基、二氟吡啶基、三氟甲基氧基吡啶基、三氟甲基吡嗪基、甲基吡嗪基、氯代吡嗪基、甲氧基哒嗪基、三氟甲基哒嗪基、氯代哒嗪基、三氟甲基嘧啶基、甲基嘧啶基、氯代嘧啶基、甲基-1,2,4-恶二唑基、甲基-1,3,4-恶二唑基;
R1选自对甲基苯基、对甲氧基苯基、对氟苯基、对氯苯基、甲基吡啶基;
R2选自甲基、乙基;R3,R4分别各自独立的选自H、甲基、乙基、甲氧羰基、乙氧羰基、乙酰基、N,N-二烷基乙酰基;或R3、R4连同它们两者所连接的N一起形成吗啉酮基、哌嗪酮基、N-甲基哌嗪酮基、甲基哌嗪酮基、吡咯烷酮基、恶唑烷酮基、咪唑烷酮基、乙酰基咪唑烷酮基、吗啉基、哌嗪基、N-乙酰基哌嗪基、吡唑基。
8.根据权利要求1所述的N-甲酰胺基吡唑啉类衍生物,其特征在于,所述通式(I)的化合物为如下化合物中的至少一种:
(S)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(1)
(R)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(1a)(S)-4-(4-甲基-2-氧代哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(4-氯苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(2)
(R)-4-(4-甲基-2-氧代哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(4-氯苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(2a)
(S)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(3)
(R)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(3a)
(S)-4-(N-甲基-N-乙氧羰基胺基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(4)
(R)-4-(N-甲基-N-乙氧羰基胺基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(4c)
(S)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((R)-1-(4-(三氟甲基)苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(5)
(R)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((R)-1-(4-(三氟甲基)苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(5a)
(S)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(3,4-二甲氧基苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(6)
(R)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(3,4-二甲氧基苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(6a)
(S)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(3,4-(亚甲基二氧)苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(7)
(R)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(3,4-(亚甲基二氧)苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(7a)
(S)-4-(3-乙酰基-2-氧代咪唑烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(4-腈基苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(8)
(R)-4-(3-乙酰基-2-氧代咪唑烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(4-腈基苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(8a)
(S)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(5-甲氧基吡啶-2-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(9)
(R)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(5-甲氧基吡啶-2-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(9a)
(S)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(5-(三氟甲基)吡啶-2-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(10)
(R)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(5-(三氟甲基)吡啶-2-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(10a)
(S)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((R)-1-(6-氯吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(11)
(R)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((R)-1-(6-氯吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(11a)
(S)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(5,6-二氟吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(12)
(R)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(5,6-二氟吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(12a)(S)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲氧基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(13)
(R)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲氧基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(13a)
(S)-4-(吗啉-4-基)-3-(4-氟苯基)-N-((R)-1-(6-甲氧基吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(14)
(R)-4-(吗啉-4-基)-3-(4-氟苯基)-N-((R)-1-(6-甲氧基吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(14a)
(S)-4-(2-(二甲胺基)-N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(15)
(R)-4-(2-(二甲胺基)-N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(15a)
(S)-4-(N-甲基-N-甲氧羰基胺基)-3-(4-甲氧基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(16)
(R)-4-(N-甲基-N-甲氧羰基胺基)-3-(4-甲氧基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(16a)
(S)-4-(4-甲基-2-氧代哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(17)
(R)-4-(4-甲基-2-氧代哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(17a)
(S)-4-(3-乙酰基-2-氧代咪唑烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(18)
(R)-4-(3-乙酰基-2-氧代咪唑烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(18a)
(S)-4-(4-乙酰哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(19)
(R)-4-(4-乙酰哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(19a)
(S)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(4-(三氟甲基)苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(20)
(R)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(4-(三氟甲基)苯基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(20a)
(S)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(21)
(R)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(21a)
(S)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(22)
(R)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(22a)
(S)-4-(2-氧代恶唑烷-3-基)-3-(5-甲基吡啶-2-基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(23)
(R)-4-(2-氧代恶唑烷-3-基)-3-(5-甲基吡啶-2-基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(23a)
(S)-4-(3-氧代吗啉-4-基)-3-(4-氟苯基)-N-((R)-1-(2-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(24)
(R)-4-(3-氧代吗啉-4-基)-3-(4-氟苯基)-N-((R)-1-(2-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(24a)
(S)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(25)
(R)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(25a)
(S)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(5-(三氟甲基)吡嗪-2-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(26)
(R)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(5-(三氟甲基)吡嗪-2-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(26a)
(S)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(5-甲基吡嗪-2-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(27)
(R)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(5-甲基吡嗪-2-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(27a)
(S)-4-(2-氧代吡咯烷-1-基)-3-(4-氟苯基)-N-((R)-1-(5-甲基吡嗪-2-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(28)
(R)-4-(2-氧代吡咯烷-1-基)-3-(4-氟苯基)-N-((R)-1-(5-甲基吡嗪-2-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(28a)
(S)-4-(2-氧代恶唑烷-3-基)-3-(4-氯苯基)-N-((R)-1-(6-(甲氧基)哒嗪-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(29)
(R)-4-(2-氧代恶唑烷-3-基)-3-(4-氯苯基)-N-((R)-1-(6-(甲氧基)哒嗪-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(29a)
(S)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)哒嗪-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(30)
(R)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(6-(三氟甲基)哒嗪-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(30a)
(S)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(6-氯哒嗪-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(31)
(R)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(6-氯哒嗪-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(31a)
(S)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(32)
(R)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(32a)
(S)-4-(3-氧代吗啉-4-基)-3-(4-氟苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(33)
(R)-4-(3-氧代吗啉-4-基)-3-(4-氟苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(33a)
(S)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(34)
(R)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(34a)
(S)-4-(3-氧代吗啉-4-基)-3-(4-氯苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(35)
(R)-4-(3-氧代吗啉-4-基)-3-(4-氯苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(35a)
(S)-4-(3-氧代吗啉-4-基)-3-(4-甲氧基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(36)
(R)-4-(3-氧代吗啉-4-基)-3-(4-甲氧基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(36a)
(S)-4-(4-乙酰哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(37)
(R)-4-(4-乙酰哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(37a)
(S)-4-(4-甲基哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(38)
(R)-4-(4-甲基哌嗪-1-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(38a)
(S)-4-(吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(39)
(R)-4-(吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(39a)
(S)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(40)
(R)-4-(2-氧代恶唑烷-3-基)-3-(4-甲基苯基)-N-((R)-1-(2-(三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(40a)
(S)-4-(3-甲基-2-氧代咪唑烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(2-三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(41)
(R)-4-(3-甲基-2-氧代咪唑烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(2-三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(41a)
(S)-4-(吡唑-1-基)-3-(4-甲基苯基)-N-((R)-1-(2-三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(42)
(R)-4-(吡唑-1-基)-3-(4-甲基苯基)-N-((R)-1-(2-三氟甲基)嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(42a)
(S)-4-(2-氧代恶唑烷-3-基)-3-(4-氯苯基)-N-((R)-1-(2-甲基嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(43)
(R)-4-(2-氧代恶唑烷-3-基)-3-(4-氯苯基)-N-((R)-1-(2-甲基嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(43a)
(S)-4-(2-氧代吡咯烷-1-基)-3-(4-氟苯基)-N-((R)-1-(2-氯嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(44)
(R)-4-(2-氧代吡咯烷-1-基)-3-(4-氟苯基)-N-((R)-1-(2-氯嘧啶-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(44a)
(S)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(3-甲基-1,2,4-恶二唑-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(45)
(R)-4-(2-氧代吡咯烷-1-基)-3-(4-甲基苯基)-N-((R)-1-(3-甲基-1,2,4-恶二唑-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(45a)
(S)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(3-甲基-1,2,4-恶二唑-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(46)
(R)-4-(3-氧代吗啉-4-基)-3-(4-甲基苯基)-N-((R)-1-(3-甲基-1,2,4-恶二唑-5-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(46a)(S)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((S)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(47)
(R)-4-(N-甲基乙酰胺基)-3-(4-甲基苯基)-N-((S)-1-(6-(三氟甲基)吡啶-3-基)乙基)-4,5-二氢-1H-吡唑-1-甲酰胺(47a)。
9.根据权利要求1所述的N-甲酰胺基吡唑啉类衍生物,其特征在于,所述在药学上可接受的盐选用药用上接受的无机酸盐、有机酸盐;所述的无机酸盐包括与氢卤酸,硝酸,碳酸,硫酸或磷酸形成的盐;所述的有机酸盐包括与苹果酸、L-苹果酸、D-苹果酸、枸橼酸、富马酸、草酸、乳酸、樟脑磺酸、L-樟脑磺酸、D-樟脑磺酸、对甲苯磺酸、甲磺酸、苯甲酸形成的盐。
10.一种权利要求1~9任一项所述N-甲酰胺基吡唑啉类衍生物单独或与其他药物联合使用在制备治疗由P2X3介导的疾病的药物中的应用。
11.根据权利要求9所述的应用,其特征在于,所述的疾病包括呼吸***疾病、多种原因造成的疼痛、皮肤疾病;所述呼吸***疾病包括慢性阻塞性肺疾病、哮喘、急性、亚急性及慢性咳嗽、支气管痉挛;所述疼痛包括手术疼痛、炎性疼痛、癌性疼痛、膀胱疼痛、子宫内膜异位症疼痛、糖尿病性神经痛、创伤性疼痛、牙痛、偏头痛、及与肠易激综合症有关的疼痛;所述皮肤疾病包括慢性瘙痒。
12.一种药物组合物,其特征在于,包括权利要求1~9任一项所述N-甲酰胺基吡唑啉类衍生物以及一种或多种药学上可接受的载体或赋形剂。
13.根据权利要求12所述的药物组合物,其特征在于,所述载体或赋形剂包括填充剂,稀释剂,湿润剂,润滑剂,粘合剂,崩解剂,吸收促进剂,表面活性剂,吸附载体,抗氧化剂、乳化剂、金属螯合剂、pH调节剂,香味剂,甜味剂中的一种或多种。
14.一种由权利要求12所述药物组合物制成的药物制剂,其特征在于,包括片剂、胶囊、吸入剂、乳剂、混悬剂、凝胶剂、粉剂、颗粒剂、口服液及注射剂。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/909,429 US20230357218A1 (en) | 2020-08-05 | 2021-06-30 | N-formamidopyrazoline derivative as p2x3 receptor antagonist and use thereof |
EP21854166.2A EP4079725A4 (en) | 2020-08-05 | 2021-06-30 | N-CARBOXAMIDOPYRAZOLINE DERIVATIVES FOR P2X3 RECEPTOR ANTAGONIST USE AND APPLICATIONS |
PCT/CN2021/103402 WO2022028154A1 (zh) | 2020-08-05 | 2021-06-30 | 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 |
JP2022548136A JP7385852B2 (ja) | 2020-08-05 | 2021-06-30 | P2x3受容体のアンタゴニストとしてのn-カルボキサミドピラゾリン系誘導体及びその使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020107775459 | 2020-08-05 | ||
CN202010777545.9A CN111892585A (zh) | 2020-08-05 | 2020-08-05 | 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113214240A true CN113214240A (zh) | 2021-08-06 |
CN113214240B CN113214240B (zh) | 2022-12-06 |
Family
ID=73246960
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010777545.9A Pending CN111892585A (zh) | 2020-08-05 | 2020-08-05 | 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 |
CN202110695453.0A Active CN113214240B (zh) | 2020-08-05 | 2021-06-23 | 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010777545.9A Pending CN111892585A (zh) | 2020-08-05 | 2020-08-05 | 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230357218A1 (zh) |
EP (1) | EP4079725A4 (zh) |
JP (1) | JP7385852B2 (zh) |
CN (2) | CN111892585A (zh) |
WO (1) | WO2022028154A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111892585A (zh) * | 2020-08-05 | 2020-11-06 | 杭州维坦医药科技有限公司 | 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1852710A (zh) * | 2003-07-15 | 2006-10-25 | 拜耳医药保健股份公司 | 用作治疗心血管疾病的par-1-拮抗剂的吡唑啉类化合物 |
CN101903348A (zh) * | 2007-12-17 | 2010-12-01 | 霍夫曼-拉罗奇有限公司 | 新型的吡唑取代的芳基酰胺 |
US20120021074A1 (en) * | 2009-03-23 | 2012-01-26 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
US20160296501A1 (en) * | 2013-12-16 | 2016-10-13 | Asana Biosciences, Llc | P2x3 and/or p2x2/3 compounds and methods |
CN111892585A (zh) * | 2020-08-05 | 2020-11-06 | 杭州维坦医药科技有限公司 | 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3803523A1 (de) * | 1987-06-12 | 1988-12-22 | Bayer Ag | Substituierte triazolinone |
US5798311A (en) * | 1990-07-13 | 1998-08-25 | Rohm And Haas Company | N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides and methods of their production |
ES2143459T3 (es) * | 1990-07-13 | 2000-05-16 | Rohm & Haas | 4,5-dihidro-1h-pirazol-1-carboxamidas n-aril-3-aril-4 sustituidas y procedimientos para su produccion. |
EP1648447A1 (de) | 2003-07-15 | 2006-04-26 | Bayer HealthCare AG | Pyrazoline als par-1-antagonisten zur behandlung von herz-kreislauf-erkrankungen |
AU2006281497B2 (en) | 2005-08-15 | 2012-06-07 | F. Hoffmann-La Roche Ag | Piperidine and piperazine derivatives as P2X3 antagonists |
EP2215049B1 (en) * | 2007-10-31 | 2019-06-12 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
WO2014053533A1 (en) | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
EP3554504B1 (en) * | 2016-12-15 | 2022-10-26 | Afferent Pharmaceuticals Inc. | Substituted pyrazole-pyrimidines, variants thereof, and uses thereof |
-
2020
- 2020-08-05 CN CN202010777545.9A patent/CN111892585A/zh active Pending
-
2021
- 2021-06-23 CN CN202110695453.0A patent/CN113214240B/zh active Active
- 2021-06-30 WO PCT/CN2021/103402 patent/WO2022028154A1/zh unknown
- 2021-06-30 US US17/909,429 patent/US20230357218A1/en active Pending
- 2021-06-30 EP EP21854166.2A patent/EP4079725A4/en active Pending
- 2021-06-30 JP JP2022548136A patent/JP7385852B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1852710A (zh) * | 2003-07-15 | 2006-10-25 | 拜耳医药保健股份公司 | 用作治疗心血管疾病的par-1-拮抗剂的吡唑啉类化合物 |
CN101903348A (zh) * | 2007-12-17 | 2010-12-01 | 霍夫曼-拉罗奇有限公司 | 新型的吡唑取代的芳基酰胺 |
US20120021074A1 (en) * | 2009-03-23 | 2012-01-26 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
US20160296501A1 (en) * | 2013-12-16 | 2016-10-13 | Asana Biosciences, Llc | P2x3 and/or p2x2/3 compounds and methods |
CN111892585A (zh) * | 2020-08-05 | 2020-11-06 | 杭州维坦医药科技有限公司 | 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 |
Non-Patent Citations (1)
Title |
---|
LAURA J.CHAMBERS ET AL.: ""Synthesis and structure–activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor"", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
Also Published As
Publication number | Publication date |
---|---|
US20230357218A1 (en) | 2023-11-09 |
EP4079725A4 (en) | 2023-07-19 |
CN111892585A (zh) | 2020-11-06 |
JP2023512579A (ja) | 2023-03-27 |
EP4079725A1 (en) | 2022-10-26 |
JP7385852B2 (ja) | 2023-11-24 |
CN113214240B (zh) | 2022-12-06 |
WO2022028154A1 (zh) | 2022-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5636434B2 (ja) | アルファ7正のアロステリックモジュレーターとしてのモルホリノチアゾール | |
AU2014224310B2 (en) | Pyrimidine carboxamides as sodium channel blockers | |
CN102271682B (zh) | 用于治疗疼痛的p2x3受体拮抗剂 | |
JP5711813B2 (ja) | βセクレターゼ(BACE)の阻害剤として有用な5,6−ジヒドロ−2H−[1,4]オキサジン−3−イル−アミン誘導体 | |
JP6908536B2 (ja) | ムスカリンm2受容体の正のアロステリックモジュレーター | |
CN103649056A (zh) | 作为离子通道调节剂的稠合杂环化合物 | |
EP2678315B1 (en) | (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR | |
AU2018234985B2 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
JP2021536436A (ja) | キノリン誘導体から調製される新規な阻害剤 | |
JP2006506380A (ja) | 月経困難症の治療用トリアゾール化合物 | |
DE19952147A1 (de) | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung | |
WO2017153578A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
JP2021526156A (ja) | ジメチルホスフィンオキシド化合物 | |
AU2019407650B2 (en) | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer | |
TW202337466A (zh) | 用於抑制ras之組合物及方法 | |
CN113214240B (zh) | 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 | |
TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
TW202033520A (zh) | 用作fgfr4抑制劑的稠環衍生物 | |
CN109641909A (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
WO2023072301A1 (zh) | 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途 | |
TW202334155A (zh) | 用於抑制ras之組合物及方法 | |
TW202220989A (zh) | 含二并環類衍生物抑制劑自由鹼的晶型及其製備方法和應用 | |
JP2017532299A (ja) | Ftl3およびjakの阻害剤としての大環状n−アリール−2−アミノ−4−アリール−ピリミジンポリエーテルの誘導体 | |
RU2800278C2 (ru) | Соединения | |
WO2024067744A1 (zh) | 杂环取代喹唑啉及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |